2M Companies, Inc.
2m.com

(printed by Dr. Kirk Kimmerling, KHG fteBac Technology on Saturday, Dec 5, 2015)

General Information
2M Companies, Inc.
4441 Buena Vista Street
75205 Dallas, Texas
United States

Founded 1986
Private ownership

2M Companies ("2M"), a Dallas-based family office and investment company focused on life science and technology companies and oil and gas mineral resources. The venture team at 2M invests in innovative, early-stage technologies that can dramatically improve people’s health and well-being. We partner with research groups, universities, inventors, and early-stage companies, investing money, time, and expertise to accelerate development of their technologies. Visit www.2m.com.

Categorization
Main sector Investor
Subsector n/a

Summary Products / Services / Technologies
No information entered

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products
No information submitted.

Technologies
No information submitted.

Financing Rounds
No information submitted.

Management
No information submitted.
Delegates

Dr. Curtis, Stephen

Delegate of company: 2M Companies, Inc., United States
Position/Function: Bioscience Ventures | Kauffman Fellow
Accele BioPharma
accelebio.com

General Information
Accele BioPharma
865 Research Parkway, Suite 400
73104 Oklahoma City, Oklahoma
United States
Founded 2011
20 employees (worldwide) (10 PhDs)
Private ownership

Accele Biopharma is a biotechnology venture accelerator. Current portfolio companies include:
Synerca Pharmaceuticals (Potentiating existing antibiotics to combat serious, resistant Gram-negative infections) - Pamlico BioPharma (next-generation antibodies therapeutics for infectious disease and cancer) - Otologic Pharmaceuticals (Treatments for protecting and restoring hearing loss) - Jortan Pharmaceuticals (BACE2 inhibitors for diabetes).

Categorization
- **Main sector**: Biotechnology - Therapeutics and Diagnostics
- **Subsector**: Anti-infectives
  - Antibodies
  - Nucleic acid drugs
  - Proteins
  - Small molecules
  - Vaccines
- **Primary therapeutic area(s)**: Infectious and parasitic diseases
  - Neoplasms / cancer / oncology
  - Endocrine, nutritional and metabolic diseases
  - Diseases of the nervous system
  - Diseases of the ear
  - Cardiovascular
  - Respiratory system

Summary Products / Services / Technologies
Synerca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing drugs that restore and enhance the effectiveness of existing antibiotics. The company’s initial program focuses on potentiating Colistin, the last line of treatment for serious Gram-Negative bacterial infections. Synerca’s candidates have demonstrated Colistin potentiation over 100-fold in resistant strains of Klebsiella, Psuedomonas, E. coli, and Acinetobacter up to 4,000x. Enhancing the efficacy and safety of Colistin would be an important development in the fight against resistant bacterial infections. Lead compounds potentiate polymyxins, carbapenems, aminoglycosides, and fluoroquinolones. Multiple combination products are in preclinical development.

Otologic Pharmaceuticals, Inc. (OPI) develops novel treatments for sensorineural, noise-induced, and age-related hearing loss. No pharmacological treatments for hearing loss are currently available. OPI’s clinical-stage program for HPN-07 plus N-acetylcycteine (NAC) recently completed a Phase 1b safety/pharmacokinetic study in healthy volunteers, and is anticipated to enter a Phase 2 trial in 2016 for the treatment of Noise-Induced Hearing Loss (NIHL) and tinnitus. OPI’s preclinical program in hair cell regeneration uses a small molecule in combination with an oligonucleotide to regrow hair cells in the cochlea and restore hearing function, making it the first potential treatment for age-related hearing loss that affects 100s of millions worldwide.

Pamlico Therapeutics is developing fully human antibody-based therapeutics against important infectious diseases and cancer. The lead program leverages fully-human antibodies - including bispecifics and ADCs - to Streptococcus pneumoniae for diagnosis and treatment of pneumococcal pneumonia. Discovery programs include HPV, Hepatitis B, tuberculosis, rabies, meningitis, and Yellow Fever.

Jortan Pharmaceuticals is developing BACE2 inhibitors for the treatment of diabetes. BACE2 has recently been identified as a key regulatory enzyme effecting pancreatic Beta-cell number and function, and is implicated in the development of hypertension. Jortan has developed potential
and selective BACE-2 (Memapsin 1) inhibitors as a novel approach to the treatment of diabetes. A drug that increases beta-cell number and function would be a very important advance in the treatment of both Type-1 ("Juvenile") and Type-2 diabetes.

### Financials

<table>
<thead>
<tr>
<th>Currencies</th>
<th>n/a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financing details</td>
<td>No information entered</td>
</tr>
</tbody>
</table>

### Collaborations and Clients

#### Partnering strategy/collaborations

Accele is interested in discussing syndicate investments or partnership opportunities for its portfolio companies.

#### Client portfolio

Accele Biopharma ("Accele") and Accele Venture Partners, a related special purpose venture fund, were formed to create a capital-efficient mechanism to identify, finance and manage groundbreaking early stage life science technologies that have the potential to dramatically improve human healthcare, have strong commercial promise and have the potential for generating early proof of concept data. Technologies across a range of therapeutic area targets are sourced from major universities or research institutes throughout the US.

Accele currently has four portfolio companies:

- **Jortan Pharmaceuticals** - BACE2 inhibition for beta cell function and mass in diabetes
- **Synereca Pharmaceuticals** - Potentiating current classes of antibiotics against life-threatening resistant bacterial infections.
- **Pamlico Biopharma** - Fully-human monoclonal antibodies for infectious disease and cancer; initial program centers on the treatment of pneumococcal pneumonia.
- **Otologic Pharmaceutics** - Novel therapeutics for the treatment of acute and age-related hearing loss.

### Products

#### Antibiotic potentiators

- **Published by**: Accele BioPharma
- **Product sector**: Biotech/Pharma
- **Partnering status**: In development

<table>
<thead>
<tr>
<th>Marketing rights available/sought</th>
<th>Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>South/South East Asia (excl. Japan)</td>
</tr>
<tr>
<td></td>
<td>Australia/New Zealand</td>
</tr>
<tr>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td>Middle East</td>
</tr>
<tr>
<td></td>
<td>South America, Central America, Mexico</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Main sector</th>
<th>Infectious and parasitic diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsector</td>
<td>Other bacterial, viral and other infectious agents as cause of other diseases</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Development phase</th>
<th>Preclinical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary market</td>
<td>Specialty</td>
</tr>
<tr>
<td>Molecule type</td>
<td>Small Molecule/NCE</td>
</tr>
<tr>
<td>Mode of administration</td>
<td>Injectable</td>
</tr>
</tbody>
</table>

**Description**

Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing drugs that restore or increase the effectiveness of existing antibiotics. Synereca has two lead research programs based on research licensed from the University of North Carolina at Chapel Hill. The first program focuses on compounds that potentiate the effectiveness of Colistin, the last line of defense against resistant Gram-Negative bacterial infections, without enhancing toxicity. The Colistin potentiation program's lead compounds shift the MIC of Colistin in several species of Gram-negative bacteria up to 500-fold in vitro and have been shown to improve the potency of Colistin in an in vivo preclinical model of infection caused by a Colistin-resistant strain of Acinetobacter baumannii. The Colistin potentiators have shown shift in minimum inhibitory concentrations for susceptible and resistant isolates of K. pneumoniae, E. coli, A. baumannii, and P. aeruginosa.

Synereca’s second program focuses on the inhibition of RecA, a key enzyme in bacterial DNA repair and the development and transmission of antibiotic resistance. Synereca’s prototype RecA inhibitors potentiate the killing of a wide variety of pathogenic bacteria by a broad range of bactericidal antibiotics.

Several Gram-Negative bacterial species, including Acinetobacter, Pseudomonas, and Klebsiella were recently given status by FDA as "Qualifying Pathogens" under the Generating Antibiotic Enccentives Now (GAIN) Act. Pursing an indication for this pathogen would provide Synereca’s product a "Qualified Infectious Disease Product" (QIDP) designation, which confers Fast-Track status, associated accelerated development and extended exclusivity benefits (an additional 5 years of regulatory exclusivity). Additionally, the Centers for Disease Control (CDC) has named multi-drug resistant Acinetobacter baumannii as a microorganism of "Threat Level – Serious" and urged development of new products addressing these types of infections.

**Clinical trials/clinical strategy**

Colistin potentiation has clinical application in several contexts. Synereca plans to initially pursue Ventilator-Associated Pneumonia caused by Gram-Negative bacteria. Colistin is also used clinically as last-line of care against multi-drug resistant Gram-Negative organisms in complicated urinary tract infection (cUTI), intra-abdominal infection (cIAI), bloodstream infections, and skin, surgical-site, and skin-structure infections (cSSSI/cSSTI). Thus, additional clinical indications provide the potential for broad label coverage in Gram-Negative bacterial infections. Similar combination products for inhalation use in cystic fibrosis patients could
then be developed as line-extensions, where inhaled Colistin therapy is common for CF patients with lung infections associated with Gram-Negative organisms.

Parenteral products containing Synereca’s potentiator compound at two concentrations (e.g. standard and 25% of standard) would be developed in combination with a fixed dose of Colistin. These products will be tested in patients with Ventilator-associated Pneumonia (VAP) caused by Gram-Negative bacteria including Acinetobacter, Pseudomonas, Klebsiella, Enterobacter, and E. coli. Synereca plans to conduct clinical studies to compare Colistin plus a potentiator in Gram-Negative infections using a nested non-inferiority/superiority design versus Colistin alone as standard of care.

**Key publications**

Synereca has identified 5 families of compounds expressing broad potentiation capabilities, including up to 500-fold improvement in the potency of Colistin against number of susceptible and resistant strains of Gram-Negative bacteria: A. baumanii, K. pneumoniae, E. coli, and P. aeruginosa (Table 1). Two prototype compounds showed a 4-fold increase in the potency of Colistin in vivo in a murine bacteremia model using an extensively Colistin-resistant strain of Acinetobacter baumanii (Ab23; Colistin MIC >8-16 ug/ml vs. 1 ug/ml for wild-type).

**Partners**

Synereca has partnered with Accele BioPharma, Inc., a biotechnology accelerator. Accele Venture Partners and additional investors have provided seed capital to Synereca in the amount of $2.5 million. Accele BioPharma is interested in discussing this program with relevant commercialization partners and potential investors.

**IP rights**

Synereca has exclusive license of patent applications currently pending at the United States Patent & Trademark Office (USPTO) from the University of North Carolina at Chapel Hill. These patents serve as the core intellectual property protection for Synereca’s products, and additional IP protection for international (WIPO) coverage for current and recently filed IP covering its compounds as antibiotic potentiators.

### BACE2 inhibitors for diabetes

**Published by** Synereca

**Product sector** Biotech/Pharma

**Partners** Accele BioPharma

**Marketing rights available/sought**

- Europe
- USA
- South/South East Asia (excl. Japan)
- Australia/New Zealand
- Canada
- Japan

**Main sector** Endocrine, nutritional and metabolic diseases

**Subsector** Type II/Non-insulin-dependent diabetes mellitus

**Development phase** Preclinical

**Primary market** GP

**Molecule type** Small Molecule/NCE

**Mode of administration** Oral

**Description**

Jortan Pharmaceuticals Inc. (JORTAN) was founded around aspartic protease inhibitors as potential diabetes therapeutics based on technology from the Oklahoma Medical Research Foundation (OMRF). BACE-2 has recently been identified as a key regulatory enzyme effecting pancreatic Beta-cell number and function (Esterhazy 2011). JORTAN has developed potent and selective BACE-2 (Memapsin 1) inhibitors as a novel approach to the treatment of diabetes. A drug that increases beta-cell number and function would be a very important advance in the treatment of both Type -1 ("Juvenile") and Type-2 diabetes.

**Clinical trials/clinical strategy**

Diabetes is the seventh leading cause of death in the US. In addition to insulin replacement, diabetes is treated with drugs that lower insulin resistance, increase insulin secretion, or alter hepatic gluconeogenesis. However none of these approaches address the progressive decrease in beta-cell function that often leads to type-2 diabetics becoming insulin dependent. A drug that increases beta-cell number and function would be a very important advance in the treatment of both Type -1 ("Juvenile") and type-2 diabetes. Importantly, inhibition of BACE-2 with small molecule inhibitors increases Beta-cell mass and glucose stimulated insulin secretion, and lowers blood glucose in diabetic mice.

**Key publications**

BACE-2 has recently been identified as a key regulatory enzyme effecting pancreatic Beta-cell number and function (Esterhazy 2011). BACE-2 cleaves the ectodomain of Tmem-27 (or collectrin), a transmembrane protein that controls Beta-cell proliferation and glucose stimulated insulin release. Down regulation of Tmem-27 by genetic modification of its transcription factor (Tcf1) causes a form of diabetes. Cleaving the ectodomain inactivates Tmem-27, which is associated with reduced Beta-cell mass and decreased insulin secretion while overexpression of Tmem-27 increases Beta-cell mass and glucose stimulated insulin secretion.

### Hearing regeneration by siRNA plus an NCE

**Published by** Synereca

**Product sector** Biotech/Pharma

**Partners** Accele BioPharma

**Marketing rights available/sought**

- Europe
- USA
- South/South East Asia (excl. Japan)
- Australia/New Zealand
- Canada
- Japan
- Middle East
- South America, Central America, Mexico

**Main sector** Diseases of the ear

**Subsector** Diseases of inner ear

**Description**

A drug that increases beta-cell number and function would be a very important advance in the treatment of both Type -1 ("Juvenile") and Type-2 diabetes.

**Clinical trials/clinical strategy**

Diabetes is the seventh leading cause of death in the US. In addition to insulin replacement, diabetes is treated with drugs that lower insulin resistance, increase insulin secretion, or alter hepatic gluconeogenesis. However none of these approaches address the progressive decrease in beta-cell function that often leads to type-2 diabetics becoming insulin dependent. A drug that increases beta-cell number and function would be a very important advance in the treatment of both Type -1 ("Juvenile") and type-2 diabetes. Importantly, inhibition of BACE-2 with small molecule inhibitors increases Beta-cell mass and glucose stimulated insulin secretion, and lowers blood glucose in diabetic mice.

**Key publications**

BACE-2 has recently been identified as a key regulatory enzyme effecting pancreatic Beta-cell number and function (Esterhazy 2011). BACE-2 cleaves the ectodomain of Tmem-27 (or collectrin), a transmembrane protein that controls Beta-cell proliferation and glucose stimulated insulin release. Down regulation of Tmem-27 by genetic modification of its transcription factor (Tcf1) causes a form of diabetes. Cleaving the ectodomain inactivates Tmem-27, which is associated with reduced Beta-cell mass and decreased insulin secretion while overexpression of Tmem-27 increases Beta-cell mass and glucose stimulated insulin secretion.
Deafness and loss of balance are commonly caused by a loss of sensory hair cells in the cochlea due to toxins, infection, trauma, aging, and other factors. Once lost, cochlear hair cells in mammals do not spontaneously regenerate, resulting in permanent hearing impairments. Several signaling pathways have been implicated as viable therapeutic targets for overcoming this regenerative barrier, including the Notch pathway.

Intercellular communication between supporting cells inhibits their ability to replace lost hair cells through transdifferentiation. Notch pathway interactions between supporting cells result in cleavage of the Notch receptor by γ-secretase complex and expression of key repressor molecules, such as HES1 (HES family bHLH transcription factor 1), that block the expression of hair cell differentiation factors such as ATOH1.

Administration of siRNA targeting HES1 depletes HES1 transcripts in supporting cells, inhibiting ATOH1 expression and promoting transdifferentiation into new hair cells.

Using this siRNA technology, the laboratory of Rick Kopke, MD, an Otologic founder, has developed a therapeutic approach to regenerate lost hair cells in the mammalian auditory (cochlea) and vestibular (balance organs, e.g. utricles) tissues of the inner ear by targeting the Notch-responsive transcriptional repressor, HES1.

Several hurdles to therapeutic regeneration of hearing are overcome with this approach:
- Regenerating both outer hair cells and inner hair cells in the cochlea
- Regenerating hair cells in the basal turn of the cochlear sensory epithelium
- Regenerating hair cells in both the striolar and extrastriolar regions in the vestibular sensory epithelia
- Regenerating hair cells in mature cochlear and vestibular sensory epithelia

Dr. Kopke has demonstrated the therapeutic efficacy of siRNA technology in promoting both de novo outer hair cell and inner hair cell formation in the cochlea and restoring hair cell numbers following toxic insults in both cochlear and vestibular sensory epithelia, including in mature structures. Using siRNA has several advantages: firstly, siRNA works at the RNA level, and no foreign DNA or viral vector are integrated into the host genome. Higher levels of siRNA molecules can be incorporated into polymer delivery carriers, and enhanced transfection can occur when compared to plasmid DNA.

These results indicate significant potential of siRNA therapeutics potential in the areas of noise-induced and age-related hearing loss, as well as vestibular disorders.

Direct administration of siRNA plus small molecule, administered intratympanically via a well-characterized nanoparticle formulation could significantly improve hearing function in patients with age-related hearing loss (presbycusis). We predict that our siRNA plus small molecule (NCE) treatment will evoke a significant degree of HC regeneration, in noise-damaged ears, which will likely be accompanied by hearing recovery across multiple frequencies. Our goal is to achieve at least a 30% reduction in ABR threshold shift in treated ears consistent with a significant increase in OHC numbers as evidenced by a reduction in DPOAE in treated ears.

Recent data regarding siRNA plus an NCE small molecule is unpublished.

Otologic Pharmaceutics has exclusive license of patent applications currently pending at the United States Patent & Trademark Office (USPTO) from the Hough Ear Institute. These patents serve as the core intellectual property protection for Otologic's products, and additional IP protection for international (WIPO) coverage for current and recently filed IP on hearing regeneration.

**Human monoclonal antibodies to treat pneumococcal pneumonia**

**Published by** Accele BioPharma

**Product sector** Biotech/Pharma

**Partnering status** In development

**Marketing rights available/sought**
- Europe
- USA
- Africa
- South/South East Asia (excl. Japan)
- Australia/New Zealand
- Canada
- Japan
- Middle East
- South America, Central America, Mexico

**Main sector** Infectious and parasitic diseases

**Subsector** Other infectious diseases

**Development phase** Preclinical
Pamlico BioPharma, Inc. develops fully human monoclonal antibodies (hmAbs) for the diagnosis and treatment of infectious diseases and cancer. Pamlico was founded on technologies from the Oklahoma Medical Research Foundation (OMRF) and Emory University to rapidly characterize and isolate fully-human monoclonal antibodies that arise from the body's natural immune response following vaccination or infection. Pamlico has successfully isolated high affinity antibodies to a wide range of human pathogens, including influenza, anthrax, rabies, varicella zoster, Japanese encephalitis, and Streptococcus pneumoniae. The company is currently focused on development of antibodies for Hepatitis B, tuberculosis, human papillomavirus, and Yellow Fever.

Pamlico's lead program is focused on severe pneumonia caused by Streptococcus pneumoniae (SPN). We have isolated antibodies to all 24 vaccine serotypes of SPN, and are in preclinical IND-directed activities for hmAbs (PneumoMab™) and a companion point-of-care (POC) diagnostic against the predominant serotypes that account for nearly 70% of SPN infections. PneumoMab is anticipated to enter clinical trials in 2016.

**Clinical trials/clinical strategy**

PneumoMab is in preclinical IND-directed toxicityology activities. In animal models of pneumonia, Pamlico's antibodies have repeatedly demonstrated reduced mortality. Clinical trials will be designed to show superiority versus standard of care antibiotics alone in the treatment of severe SPN-CAP (PSI grade IV-V). In parallel, Pamlico is developing a companion point-of-care (POC) lateral-flow diagnostic to identify patients eligible for PneumoMab therapy within 20 minutes.

Pamlico's mAbs are targeted at S. pneumoniae, recently classified as a “Qualifying Pathogen” under the recent “Generating Antibiotic Incentives Now” (GAIN) Act. PneumoMab will be submitted to FDA as a “Qualified Infectious Disease Product” (QIDP), which may confer Fast-Track status as well as an additional 5 years of exclusivity for a total eligible market exclusivity of 12-17 years.

**Key publications**


**Partners**

Pamlico has partnered with Accele BioPharma, Inc., a biotechnology accelerator. Accele Venture Partners has provided seed capital to Pamlico to fund initial development milestones. Pamlico is supported by strong intellectual property, has shown early success in validated preclinical models, and has significant commercial potential in the field of infectious diseases. Accele BioPharma is interested in discussing this program and related intellectual property with investors and relevant commercialization partners.

**IP rights**

Pamlico has licensed one issued and one patent currently pending at the United States Patent & Trademark Office (USPTO) from Emory University and Oklahoma Medical Research Foundation, respectively. These patents serve as the core intellectual property protection for Pamlico's product, and additional IP protection for international (WIPO) coverage for current and new IP is anticipated.

**NHPN-1010 for acute sensorineural hearing loss**

**Published by**

Accele BioPharma

**Product sector**

Biotech/Pharma

**Partnering status**

Available for out-licensing

**Marketing rights available/sought**

Europe

USA

Africa

South/South East Asia (excl. Japan)

Australia/New Zealand

Canada

Japan

Middle East

South America, Central America, Mexico

**Main sector**

Diseases of the ear

**Subsector**

Diseases of inner ear

**Development phase**

Phase I

**Primary market**

Specialty

**Molecule type**

Small Molecule/NCE

**Mode of administration**

Oral

Pamlico has successfully isolated high affinity antibodies to a wide range of human pathogens, including influenza, anthrax, rabies, varicella zoster, Japanese encephalitis, and Streptococcus pneumoniae. The company is currently focused on development of antibodies for Hepatitis B, tuberculosis, human papillomavirus, and Yellow Fever. Pamlico's lead program is focused on severe pneumonia caused by Streptococcus pneumoniae (SPN). We have isolated antibodies to all 24 vaccine serotypes of SPN, and are in preclinical IND-directed activities for hmAbs (PneumoMab™) and a companion point-of-care (POC) diagnostic against the predominant serotypes that account for nearly 70% of SPN infections. PneumoMab is anticipated to enter clinical trials in 2016.


Pamlico has partnered with Accele BioPharma, Inc., a biotechnology accelerator. Accele Venture Partners has provided seed capital to Pamlico to fund initial development milestones. Pamlico is supported by strong intellectual property, has shown early success in validated preclinical models, and has significant commercial potential in the field of infectious diseases. Accele BioPharma is interested in discussing this program and related intellectual property with investors and relevant commercialization partners.

Pamlico has licensed one issued and one patent currently pending at the United States Patent & Trademark Office (USPTO) from Emory University and Oklahoma Medical Research Foundation, respectively. These patents serve as the core intellectual property protection for Pamlico's product, and additional IP protection for international (WIPO) coverage for current and new IP is anticipated.

**NHPN-1010 for acute sensorineural hearing loss**

**Published by**

Accele BioPharma

**Product sector**

Biotech/Pharma

**Partnering status**

Available for out-licensing

**Marketing rights available/sought**

Europe

USA

Africa

South/South East Asia (excl. Japan)

Australia/New Zealand

Canada

Japan

Middle East

South America, Central America, Mexico

**Main sector**

Diseases of the ear

**Subsector**

Diseases of inner ear

**Development phase**

Phase I

**Primary market**

Specialty

**Molecule type**

Small Molecule/NCE

**Mode of administration**

Oral

Pamlico has successfully isolated high affinity antibodies to a wide range of human pathogens, including influenza, anthrax, rabies, varicella zoster, Japanese encephalitis, and Streptococcus pneumoniae. The company is currently focused on development of antibodies for Hepatitis B, tuberculosis, human papillomavirus, and Yellow Fever. Pamlico's lead program is focused on severe pneumonia caused by Streptococcus pneumoniae (SPN). We have isolated antibodies to all 24 vaccine serotypes of SPN, and are in preclinical IND-directed activities for hmAbs (PneumoMab™) and a companion point-of-care (POC) diagnostic against the predominant serotypes that account for nearly 70% of SPN infections. PneumoMab is anticipated to enter clinical trials in 2016.


Pamlico has partnered with Accele BioPharma, Inc., a biotechnology accelerator. Accele Venture Partners has provided seed capital to Pamlico to fund initial development milestones. Pamlico is supported by strong intellectual property, has shown early success in validated preclinical models, and has significant commercial potential in the field of infectious diseases. Accele BioPharma is interested in discussing this program and related intellectual property with investors and relevant commercialization partners.

Pamlico has licensed one issued and one patent currently pending at the United States Patent & Trademark Office (USPTO) from Emory University and Oklahoma Medical Research Foundation, respectively. These patents serve as the core intellectual property protection for Pamlico's product, and additional IP protection for international (WIPO) coverage for current and new IP is anticipated.
noise-induced, chemical-induced, acute sensorineural, tinnitus, and age-related hearing loss. Hearing loss costs the nation $56B per year in lost productivity, retraining and health care for the hard of hearing (Centers for Disease Control).

One in four individuals will develop a permanent hearing loss as a result of their occupational and recreational exposure to noise hazards. Noise-induced hearing loss is the most common occupational disease and the second most self-reported occupational illness or injury (National Institute of Occupational Health and Safety). It is estimated that 26 million Americans between the ages of 20 and 69 have significant sensorineural hearing loss likely resulting from loud noise exposure. Up to 600,000 military personnel exposed to high noise environments are at risk for hearing loss. Approximately 300,000 civilian patients seek treatment within 48 hours of noticing hearing loss. Among U.S. active duty military, the incidence rate is much larger. Blast-induced trauma accounts for more than 80% of battlefield injuries that occur during current military conflicts. Sensorineural hearing loss, tinnitus, hyperacusis, memory impairment and anxiety/irritability are frequently result from blast exposure. Action on Hearing Loss estimates the drug market for noise-induced hearing loss at around $2 billion annually.

**Clinical trials/clinical strategy**

NHPN-1010 is an oral, fixed-dose combination of N-acetyl-cysteine (NAC) and 2,4-disulfo-a-phenyl-tert-butylnitrone (HPN-07). Each compound has extensive preexisting individual clinical data. In combination, they have produced extensive and strongly positive in vivo results in models of hearing loss. NAC has long been known for hearing treatment while experiments with HPN-07 were only contemplated in the last decade. HPN was developed by OMRF scientists and licensed as a potential anti-stroke drug by AstraZeneca in collaboration with Renovis Pharmaceuticals. HPN-07 progressed through Phase 3 clinical trials in humans, but while the treatment caused no adverse reactions in 3,000 stroke patients, it was ineffective in acute ischemic stroke. OPI licensed patents on the combination of the two compounds for the treatment and prevention of hearing loss.

In animal models, combinational antioxidant treatment with NHPN-1010 (HPN-07 plus NAC) preserves the cellular and functional attributes of the inner ear and cochlear nucleus after intense noise exposure (115 dB). Following an intense acute acoustic trauma hearing loss, as measured by auditory brainstem responses, substantially recovers in rats treated with a 3-day therapeutic regimen of NHPN-1010. Consistent with this antioxidant-mediated functional recovery, the acute acoustic trauma-induced loss of audiosensory epithelia (i.e. outer hair cells) is markedly (85%) reduced by NHPN-1010 intervention. Moreover, auditory brain wave I responsiveness, as measured by input/output function, is also preserved by this intervention strategy, demonstrating sustained functional integrity of the inner hair cell afferent nerve synapse. This is notable as it can be the difference between patients requiring hearing aids or not. Thus, NHPN-1010 intervention not only maintains auditory neural responsiveness and preserves outer hair cell populations but also protects against the progressive loss of afferent nerve synapses.

We have demonstrated that combination treatment of NAC plus HPN-07 significantly reduced hearing loss and cochlear hair cell death in multiple animal models when administered after exposure to loud noise and to blast overpressure compared to either agent alone. NHPN-1010 is currently being evaluated in a Phase 1 safety/pharmacokinetic study in healthy volunteers, and OPI anticipates entering Phase 2 trials in 2016 for acute noise-induced hearing loss and cisplatin-induced hearing loss.

**Key publications**


**Partners**

OPI has partnered with Accele BioPharma, Inc., a biotechnology accelerator. OPI is supported by strong intellectual property, has shown early success in validated preclinical models, and has significant commercial potential in the field of hearing loss. Accele BioPharma is interested in discussing this program and related intellectual property with investors and relevant commercialization partners.

**IP rights**

Otolologic Pharmaceuticals, Inc. (OPI) has obtained exclusive license to NHPN-1010, a combination of two antioxidant molecules as a potential therapeutic for sensorineural, noise-induced, and chemotherapy-induced hearing loss based on technology from the Oklahoma Medical Research Foundation (OMRF), the Hough Ear Institute, the US Office of Naval Research, and American BioHealth Group.

http://www.partneringone.com/partnering/profile_full.php?id=825024ffe7f8b9d5f55ggwc&print=1
Technologies

No information submitted.

Financing Rounds

Round 1: 02.01.2011

Type/Series: Accele Venture Partners, LP I
Stage/type of financing: Equity - Start-up
Investment: USD m 10.00
Valuation: USD m n/a
Lead investors: Limited partners
Co-investors:

Remarks: AVP I was closed in January 2011, and has been fully committed to the firm's four portfolio companies: Jortan Pharmaceuticals (Seed), Synereca Pharmaceuticals (Seed), Pamlico Biopharma (Seed, Series A), and Otologic Pharmaceuticals (Series A). Accele syndicates investments in its portfolio companies with established life science investors and partners.

Management

Mr. Briggs, Justin Vice President, Business Development
Mr. Duncan, Clayton CEO, Chairman
Dr. Gammans, Richard COO and President
Dr. Hamm, Elaine Vice President, Research Operations

Delegates

Mr. Briggs, Justin

Delegate of company: Accele BioPharma, United States
Position/Function: Vice President - Business Development
Professional background: Justin Briggs is an experienced drug development executive, with a focus on business development, regulatory affairs, clinical and financial management for early stage biotechnology companies. Mr. Briggs currently serves as Vice President, Business Development and Operations for Accele BioPharma and Venture Partner, Accele Venture Partners. Previously, he served as Manager of Corporate Development & Operations for Altheus Therapeutics, and various roles at Crescendo Biosciences (acquired, Myriad Genetics; $270M), Mintiva, and KemmX Corp.

Current and previous affiliations: Accele BioPharma
Accele Venture Partners
Jortan Pharmaceuticals (BACE2 inhibitors, diabetes)
Pamlico BioPharma (human antibodies for infectious disease and cancer)
Synereca Pharmaceuticals (antibiotic potentiation)
Otologic Pharmaceuticals (hearing loss)

Previous:
Altheus Therapeutics
Crescendo Biosciences (acquired, Myriad Genetics)
PolySkope Laboratories
Mintiva
KemmX
Southwest Nanotechnologies
Bayer Pharma AG
www.bayerpharma.com

General Information
Bayer Pharma AG
Muellerstr. 178
13353 Berlin
Germany

Founded 1863
56000 employees (worldwide)
Public

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions.

Bayer Pharmaceuticals is the pharmaceutical division of Bayer AG. We market our products in more than 100 countries, and in 2014 generated sales of €12 billion. Around 39,000 members of staff currently work for Bayer Pharmaceuticals worldwide – approximately 8,000 in research and development alone.

We aim to improve people’s quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products. In this context, Bayer Pharmaceuticals uses experience it has gained from over a century in the business.

We concentrate on the following major therapeutic groups in which we make fundamental contributions to medical progress:

- Cardiovascular and blood diseases
- Oncological diseases
- Ophthalmology
- Women’s healthcare

Categorization

<table>
<thead>
<tr>
<th>Main sector</th>
<th>Pharma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsector</td>
<td>Anti-infectives</td>
</tr>
<tr>
<td></td>
<td>Antibodies</td>
</tr>
<tr>
<td></td>
<td>Drug delivery</td>
</tr>
<tr>
<td></td>
<td>Molecular diagnostics</td>
</tr>
<tr>
<td></td>
<td>Proteins</td>
</tr>
<tr>
<td></td>
<td>Small molecule therapeutics</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primary therapeutic area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious and parasitic diseases</td>
</tr>
<tr>
<td>Neoplasms / cancer / oncology</td>
</tr>
<tr>
<td>Diseases of the blood and blood-forming organs; immune disorders</td>
</tr>
<tr>
<td>Diseases of the nervous system</td>
</tr>
<tr>
<td>Diseases of the eye</td>
</tr>
<tr>
<td>Cardiovascular</td>
</tr>
<tr>
<td>Respiratory system</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue</td>
</tr>
<tr>
<td>Genitourinary system</td>
</tr>
</tbody>
</table>

Summary Products / Services / Technologies
Kogenate
Betaferon / Betaseron
Xarelto
YAZ/Yasmin / Yasminelle
Nexavar
Mirena
Adalat
Aspirin
Avalox / Avelox
Glucobay
Eylea
Levitra

http://www.partneringone.com/partnering/profile_full.php?id=8238344f5b7zhmNdGu6xc&print=1
Delegate of company: Bayer Pharma AG, Germany
Position/Function: Head BD&L Operations

Mr. Chen, Aaron
Delegate of company: Bayer Pharma, United States
Position/Function: Director BD&L Specialty Medicine

Dr. Martin, Lucas
Delegate of company: Bayer AG, United States
Position/Function: Senior Director BD&L Early Licensing

Dr. Wolters, Mark
Delegate of company: Bayer Pharma AG, Germany
Position/Function: Head Early Licensing
Bioengine Venture Capital

Bioengine Venture Capital
7F, N.3-2, Park St.
115 Taipei City
Taiwan

BioEngine Technology Development is the venture unit that invests in new ventures in life sciences and medical technologies. Our team is Taiwan based with international experience that brings together the best of science, business and operations. We have a proven track record in investing in the life-sciences with over $300M USD under management and several IPOs in public markets on the Taiwan and Hong Kong exchanges. The portfolio consists primarily of early-stage investments, with some later stage value investments. Our core focus is to look for game-changing companies that would have a meaningful impact on patients lives globally.

Categorization

Main sector Investor
Subsector Venture capital fund

Summary Products / Services / Technologies

No information entered

Financials

Currencies n/a

Collaborations and Clients

Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products

Biosimilar oncology

Published by Bioengine Venture Capital
Product sector Biotech/Pharma
Partnership status Available for out-licensing
Marketing rights available/sought

Main sector Neoplasms / cancer / oncology
Subsector n/a
Development phase Preclinical
Molecule type Antibody
Mode of administration Injectable

Biosimilar RA (multiple)

Published by Bioengine Venture Capital
Product sector Biotech/Pharma
Partnership status Available for out-licensing
Marketing rights available/sought Europe

USA
Africa
Australia/New Zealand
Canada
Japan
Middle East
South America, Central America, Mexico
Main sector Musculoskeletal system and connective tissue
Subsector Rheumatoid arthritis
Development phase Preclinical
Primary market Specialty
Molecule type Antibody
LT1001

Published by Bioengine Venture Capital
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
  Europe
  USA
  Africa
  Australia/New Zealand
  Canada
  Japan
  Middle East
  South America, Central America, Mexico
Main sector Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Subsector Pain
Development phase Phase III
Mode of administration Injectable
Description The First Injectable One-Week-Acting Analgesic.
Clinical trials/clinical strategy 505(b)(2) pathway in local markets to be conducted. Completed Phase 2/3 in Taiwan and NDA submission in Q4 2015

Partners Looking for partner in other markets.
IP rights Global

Technologies
No information submitted.

Financing Rounds
No information submitted.

Management
No information submitted.

Delegates
Dr. Tsai, Richard
  Delegate of company: Bioengine Venture Capital, Taiwan
  Position/Function: Partner
Biogeneration Ventures
www.biogenerationventures.com

(printed by Dr. Kirk Kimmerling, KHG fiteBac Technology on Saturday, Dec 5, 2015)

**General Information**

*Biogeneration Ventures*
Gooimeer 2-35
1411dc Naarden
Netherlands

*Founded 2006*

BioGeneration manages venture capital funds investing in life sciences companies in The Netherlands, Belgium and Germany. BioGeneration acts as an active lead investor and typically enters at the seed, series A or B rounds with a broad focus on across all life sciences sectors.

**Categorization**

*Main sector* Investor
*Subsector* n/a

**Summary Products / Services / Technologies**

*No information entered*

**Financials**

*Currencies* n/a
*Financing details* No information entered

**Collaborations and Clients**

*Partnering strategy/collaborations*
Looking for investment opportunities in The Netherlands, Belgium and Germany.

*Client portfolio*
No information entered

**Products**

*No information submitted.*

**Technologies**

*No information submitted.*

**Financing Rounds**

*No information submitted.*
Management

No information submitted.

Delegates

Dr. Couto, Daniela
Delegate of company: Biogeneration Ventures, Netherlands
Position/Function: Senior Associate

Mr. van Wezel, Edward
Delegate of company: Biogeneration Ventures, Netherlands
Position/Function: Managing director
Cambridge Innovation Capital Plc

www.cambridgeinnovationcapital.com

General Information
Cambridge Innovation Capital Plc
The Hauser Forum
3 Charles Babbage Road
CB3 0GT CAMBRIDGE
United Kingdom

Founded 2013

Cambridge Innovation Capital ("CIC") was launched with initial funding from long-term institutional and strategic investors including Invesco Perpetual, Lansdowne Partners and the University of Cambridge Endowment Fund. We invest in high-growth life science and technology companies arising from the University of Cambridge and the wider Cambridge Cluster. With our close ties to the University, active angel groups and the entrepreneurial community, our mission is to be one of the leading venture capital investors in the vibrant Cambridge Cluster. Where needed, our investment strategy backed by our permanent capital structure, allows us to provide long-term financial support to our portfolio companies. In the life sciences we invest across a range of areas with a focus on IP rich companies with the great potential.

Categorization
Main sector Investor
Subsector Venture capital fund

Summary Products / Services / Technologies
No information entered

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products
No information submitted.

Technologies
No information submitted.

Financing Rounds
No information submitted.

Management
No information submitted.

Delegates
Dr. Tansley, Robert

Delegate of company: Cambridge Innovation Capital Plc, United Kingdom
Division/Department: Life Science
Position/Function: Investment Director
Deals you have been involved in:
- Congenica - Genome analysis company
- Abcodia - Early cancer detection
- Iceni Therapeutics - Epigenetics discovery company
- Inivata - Clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients
- Morphogen-IX - Drug discovery company in field of pulmonary arterial hypertension
CrystalGenomics, Inc.

CrystalGenomics (CG) is a clinical stage biopharmaceutical company focused in the discovery and development of novel therapeutics in the unmet medical need areas of inflammation, oncology, and infectious diseases.

We are seeking in-licensing opportunities to strengthen our pipeline. We are opportunistic and open to considering therapeutic areas outside of our main focus for first-in-class candidates (both small & large molecules) where clear unmet medical needs exist.

We are also looking to partner our therapeutic programs for further development and commercialization outside of Korea, and would consider both out-licensing and co-development possibilities.

IPO (year) 2006
Primary ticker symbol 083790 (KOSDAQ)
Primary stock exchange other

Categorization
Main sector Biotechnology - Therapeutics and Diagnostics
Subsector Anti-infectives
Small molecules
Primary therapeutic area(s) Infectious and parasitic diseases
Neoplasms / cancer / oncology
Diseases of the nervous system
Musculoskeletal system and connective tissue

Summary Products / Services / Technologies
(1) Acelex® (polmacoxib) - Next generation NSAID with novel mechanism of action (dual COX-2 & carbonic anhydrase inhibitor); approved by the MFDS and launched in Korea (marketed and sold by Dong-A ST)

(2) CG400549 - First-in-class antibiotic (FabI inhibitor) for MRSA and other serious infections associated with Staph aureus. Completed a Phase 2a proof-of-concept study where CG400549 demonstrated 100% clinical cure rate against MRSA in skin infection (ABSSSI).

(3) CG200745 - Potentially best-in-class HDAC inhibitor for solid and liquid tumors; Phase 1 completed and a Phase 1b/2 study is currently underway for refractory MDS (orphan indication approved); Phase 1b/2 study ongoing concurrently for pancreatic ductal adenocarcinoma (PDAC)

(4) CG026806 - BTK/FLT3 inhibitor for treatment of AML. Recent literature has shown the importance of BTK in AML, especially in cells with FLT3 resistance.

(5) KMO Inhibitor for Neurodegenerative Diseases such as Huntington's Disease and Alzheimer's Disease (discovery)

(6) HIF-PH program for anemia (discovery)

(7) FXR agonist for liver diseases (discovery)

For programs in clinical or preclinical stage, we would like to consider both licensing and co-development models.

For programs in early discovery (KMO, HIF-PH, FXR), we would be interested in risk-sharing R&D collaborations with partners that have relevant expertise in each of the corresponding disease areas.

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
Our business model is to independently conduct from discovery through early POC (either preclinical or clinical), then out-partner these therapeutic programs to international partner(s) for further development and commercialization in the ex-Korea territory.

Client portfolio
Amore Pacific
Asan Medical Center
AstraZeneca AB
Carna Biosciences
Daiichi-Sankyo
Hanmi Pharmaceuticals
Hanwha VC
Kissei Pharmaceutical Co., Ltd
OncoTherapy Science, Inc.
Oxford Bioscience Partners
Palkion and ProQuest Investments
Pohang Accelerator Laboratory
Rigel Pharmaceutical
SoftBankInvestment-Biotech
Tanabe Seiyaku Co., Ltd
YuYu Pharma
Dong-A ST

Products

Acelex® (polmacoxib) - Next Generation NSAID for Osteoarthritis
Published by CrystalGenomics, Inc.
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Europe
USA
Africa
South/South East Asia (excl. Japan)
Australia/New Zealand
Canada
Commonwealth of Independent States (CIS)
Japan
Middle East
South America, Central America, Mexico
Main sector Musculoskeletal system and connective tissue
Subsector Other joint disorders
Development phase On the Market
Primary market GP
Molecule type Small Molecule/NCE
Mode of administration Oral
Description
Acelex® (polmacoxib) is a novel NSAID for osteoarthritis with tissue-specific mechanism of action. It has been approved in Korea and is marketed and sold by Dong-A ST (for the Korean market).

To this date, more than several hundred patients have been dosed on polmacoxib and based on clinical data thus far; polmacoxib is projected to have excellent efficacy and safety profiles.

Phase 2b and 3 studies included a 6-week active comparator arm of celecoxib and demonstrated that the 2mg/day dose of polmacoxib was at least non-inferior to 200mg/day of celecoxib in subjects with osteoarthritis in terms of both safety and efficacy. At the midpoint of the study, Week 3, polmacoxib showed superior efficacy over celecoxib in terms of quicker onset of relief as patients dosed with polmacoxib showed faster relief of signs and symptoms of osteoarthritis.

We are actively pursuing out-partnering ex-Korea.

CG026806 (BTK/FLT3 Inhibitor for Hematologic Cancers)
Published by CrystalGenomics, Inc.
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Europe
USA
Africa
CG026806 is a polypharmacological multi-kinase inhibitor that blocks the activity of BTK and FLT3.

Recent literature has stressed the importance of BTK inhibition in targeting AML cancer cells, especially in FLT3 mutations.

Exposures observed from the PK studies suggest that it would be possible to develop CG026806 as a once a day, oral therapeutic.

CG026806 demonstrated excellent anti-cancer effects in Mino and MV4-11 xenograft studies.

CG026806 did not show any signs of toxicity from the 2-week toxicity study in mouse even at the highest dose of 450 mg/kg.

CG200745 is an anti-cancer agent that deactivates HDAC, an enzyme that catalyzes the histone deacetylation. CG200745 showed a better profile when compared with other compounds in the same class such as Zolinza®, of Merck & Co. in a series of anti-cancer efficacy tests using various cancer cell lines and xenograft animal models. CG200745 is also highly soluble.

CG200745 has demonstrated excellent efficacy in its early clinical development as 6 out of 10 stable diseases (SD) were observed in all solid tumor patients from the single ascending dose study.

Overall, 56% of patients had stable disease from the phase 1 study and notable cases included a pancreatic cancer patient from part one of the study (single dose) who had stable disease for up to 7 cycles, and a colorectal cancer patient from part two of the study (Multiple dose) had stable disease up to 11 cycles. In the case of the colorectal cancer patient sub group, nearly 80% had stable disease.

In addition to superb efficacy and safety demonstrated so far, CG200745 has shown excellent PK and PD profiles and there is a high probability that it can be developed for a variety of solid and hematologic tumor indications including Hepatocellular carcinoma, colorectal, pancreatic cancer and AML.

- Currently in PhI/IIb study for MDS (orphan approved); concurrently in PhI/IIb study for pancreatic ductal adenocarcinoma (PDAC)
Marketing rights available/sought
- Europe
- USA
- Africa
- South/South East Asia (excl. Japan)
- Australia/New Zealand
- Canada
- Commonwealth of Independent States (CIS)
- Japan
- Middle East
- South America, Central America, Mexico

Main sector: Infectious and parasitic diseases
Subsector: n/a

Development phase: Phase II

Molecule type: Small Molecule/NCE

Mode of administration: Oral

Description:
- CG400549 is a novel antibiotic candidate for MRSA. Obtained human POC and completed Phase 2a study in the US. Both Phase 1 Single Ascending Dose and Phase 1 Multiple Ascending Dose studies have been completed in the EU.

- CG400549 inhibits enoyl-[acyl-carrier-protein] (ACP) reductase (FabI), an essential enzyme in fatty acid synthesis. Since fatty acids are an ingredient of bacterial cell walls, its synthesis is critical for the survival of bacteria. A FabI inhibitor could possess antibacterial activity against pathogens in which FabI is the sole enoyl-ACP reductase including but not limited to Staphylococcus aureus, Haemophilus influenza, Moraxella catarrhalis, and Escherichia coli.

- From the Phase 2a POC study, 90.9% of evaluable subjects had early clinical response at the ECE visit (48 to 72 hours after enrollment or Day 3~4) and 100% of evaluable subjects were clinically cured by the TOC visit (Day 21~28)

First in class oncology therapeutic
Published by CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Seeking for in-licensing

Marketing rights available/sought
- Main sector: Neoplasms / cancer / oncology
- Subsector: n/a

Development phase: Lead optimization

First in class oncology therapeutic
Published by CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Seeking for in-licensing

Marketing rights available/sought
- Main sector: Neoplasms / cancer / oncology
- Subsector: n/a

Development phase: Preclinical

First in class oncology therapeutic
Published by CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Seeking for in-licensing

Marketing rights available/sought
- Main sector: Neoplasms / cancer / oncology
- Subsector: n/a

First in class orphan indication therapeutic
Published by CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Seeking for in-licensing

Marketing rights available/sought
- Main sector: Neoplasms / cancer / oncology
- Subsector: n/a

First in class therapeutic for CNS and other nervous system related diseases
Published by CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Seeking for in-licensing

Marketing rights available/sought
- Main sector: Diseases of the nervous system
- Subsector: n/a

First in class therapeutic for infectious diseases including hepatitis B/C, gram-neg antibiotic resistant bacteria
Published by CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Seeking for in-licensing
Marketing rights available/sought
Main sector: Infectious and parasitic diseases
Subsector: n/a

First in class therapeutic for liver diseases
Published by: CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Seeking for in-licensing
Marketing rights available/sought
Main sector: Digestive system
Subsector: n/a

First in class therapeutic for type I/type II diabetes
Published by: CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Seeking for in-licensing
Marketing rights available/sought
Main sector: Endocrine, nutritional and metabolic diseases
Subsector: n/a

FXR Agonist for Liver Diseases
Published by: CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Available for out-licensing
Marketing rights available/sought
Main sector: Endocrine, nutritional and metabolic diseases
Subsector: n/a
Development phase: Discovery

HIF-PH Inhibitor for Anemia
Published by: CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Available for out-licensing
Marketing rights available/sought: Europe
Main sector: Endocrine, nutritional and metabolic diseases
Subsector: Other endocrine and metabolic disorders
Development phase: Discovery
Primary market: GP
Molecule type: Small Molecule/NCE
Mode of administration: Oral
Description: HIF-PH inhibitor being developed to treat anemia as an oral therapeutic

KMO Inhibitor for Neurodegenerative Diseases
Published by: CrystalGenomics, Inc.
Product sector: Biotech/Pharma
Partnering status: Available for out-licensing
Marketing rights available/sought: Europe
Main sector: Mental and behavioural disorders
Subsector: n/a
Development phase: Discovery
Primary market: GP
Molecule type: Small Molecule/NCE
Mode of administration: Oral
Description: KMO Inhibitor for Neurodegenerative Diseases such as Huntington's Disease and Alzheimer's Disease
Technologies

No information submitted.

Financing Rounds

No information submitted.

Management

Mr. Ahn, Sang-Cheon  Executive Managing Director
Mr. Cho, Young-Hyun  VP, Medical and Pharmaceutical Business
Dr. Cho, Joong Myung  Chairman & CEO
Dr. Ro, Seonggu  EVP & CTO

Delegates

Dr. Cho, Joong Myung

Delegate of company:  CrystalGenomics, Inc., Korea, South
Position/Function:  Chairman & CEO

Mr. Cho, Lynn

Delegate of company:  CrystalGenomics, Inc., Korea, South
Division/Department:  Business Development
Position/Function:  Associate, Business Development

Mr. Kim, Steven

Delegate of company:  CrystalGenomics, Inc., Korea, South
Division/Department:  Business Development
Position/Function:  Director, Business Development
DEL BioPharma
www.DELbiopharma.com

General Information

DEL BioPharma
37 Lakewood Circle
94402 San Mateo, California
United States

Private ownership

DEL BioPharma provides innovative strategies to biopharmaceutical organizations of all sizes from established and fully integrated companies to start-ups looking for proof of concept.

Founder Daniel E. Levy received his Ph.D. in organic chemistry from MIT and his B.S. degree from the University of California - Berkeley. Since 1992, Dr. Levy worked with companies in all capacities from consultant to director. His broad experience in drug discovery provides him a unique perspective enabling him to address issues at the interface of chemistry and biology long before they impede progress.

Dr. Levy has strategies for addressing the most challenging problems independent of therapeutic area or biological target. With a strong focus on PK/ADME, pre-formulation, toxicity and scale-up issues, new paradigms for discovery research are applied. Through early parallel screening and incorporation of CRO activities, the pathway to success is accelerated.

Categorization

Main sector Biotechnology - Therapeutics and Diagnostics
Subsector Anti-infectives
Antibodies
Drug delivery
Nucleic acid drugs
Small molecules

Primary therapeutic area(s)
Neoplasms / cancer / oncology
Endocrine, nutritional and metabolic diseases
Diseases of the nervous system
Cardiovascular
Skin and subcutaneous tissue
Musculoskeletal system and connective tissue
Injury, poisoning and certain other consequences of external causes

Summary Products / Services / Technologies

• Design and implementation of medicinal chemistry programs
• Outsource management (research scale through clinical development)
• Corporate due diligence
• Finance/partnering facilitation

Financials

Currencies n/a

Financing details No information entered

Collaborations and Clients

Partnering strategy/collaborations
No information entered

Client portfolio
No information entered

Products

No information submitted.

Technologies

No information submitted.
Financing Rounds

*No information submitted.*

Management

*No information submitted.*

Delegates

Dr. Levy, Daniel

**Delegate of company:** DEL BioPharma, United States

**Position/Function:** Owner/Principal

**Partnering objectives:**

- Finance and Partnering Facilitation
- Outsourcing (chemistry, manufacturing, formulations, clinical, etc)
- Project oversight and management

Through strategic combinations of contract research organizations, in-house resources and accessibility to the investment community, new projects are implemented and existing projects are accelerated.

**Professional background:** Dr. Levy is an experienced organic/medicinal chemist having contributed to the design of novel therapeutic agents targeting cardiovascular disease, cancer and inflammatory disorders. Since 1992, Dr. Levy led interdisciplinary teams focused on kinase inhibitors, GPCR antagonists, matrix metalloproteinase inhibitors and cell adhesion molecules. He is also responsible for successful pairings between companies and investors. His work is documented in almost 30 peer reviewed publications and over 11 issued/published United States patents.

Having held positions at Glycomed, COR Therapeutics and Scios, Dr. Levy’s most recent role was Director of Synthetic Chemistry at Intradigm Corporation designing novel nanoparticle delivery vehicles siRNA-based therapeutics. He has broad experience in the chemistry of amino acids/peptides, heterocycles, polyethylene glycols and lipids. As a consultant, Dr. Levy provides strategic guidance and program implementation services to companies interested in small molecule drug discovery/development, diagnostics, drug delivery and microfluidics. Set-up and management of outsourcing activities is a key service supporting these sectors. Additionally, he provides technical due diligence services, facilitates intellectual property development and supports the filing of grant application.

Dr. Levy received his Ph.D. in organic chemistry from the Massachusetts Institute of Technology and his B.S. in chemistry from the University of California - Berkeley. He is the author/editor of three books addressing aspects of carbohydrate chemistry and mechanistic organic chemistry.

**Primary area of expertise:**

- Design and implementation of medicinal chemistry programs
- Outsource management (research scale through clinical development)
- Corporate due diligence
- Finance/partnering facilitation

**Current and previous affiliations:**

- DEL BioPharma - Owner and Principal Consultant
- Intradigm Corporation - Director of Synthetic Chemistry
- Scios - Group Leader, Medicinal Chemistry
- COR Therapeutics - Senior Scientist, Medicinal Chemistry
- Glycomed, Inc. - Scientist, Medicinal Chemistry
Eclsoion2 SA
www.eclosion2.com

Eclsoion2 SA  
14, Chemin des Aulx  
1228 Plan-Les-Ouates  
Switzerland

Eclsoion2 is an investment fund based in Switzerland that focuses on building companies from the ground up through a public-private partnership. We have successfully built companies taking them from idea through to clinical PoC (e.g. GeNeuro, GenKyoTex).

Categorization

Main sector: Investor  
Subsector: Venture capital fund

Summary Products / Services / Technologies

No information entered

Financials

Currencies: n/a  
Financing details: No information entered

Collaborations and Clients

Partnering strategy/collaborations: No information entered  
Client portfolio: No information entered

Products

No information submitted.

Technologies

No information submitted.

Financing Rounds

No information submitted.

Management

No information submitted.

Delegates

Dr. Parker, Andrew

Delegate of company: Eclsoion2 SA, Switzerland  
Position/Function: General Partner  
Partnering objectives: Eclsoion is an investment fund based in Switzerland that focuses on building companies from the ground up through a public-private partnership.
Professional background: Andy has twenty years experience in the pharmaceutical and biotechnology industry leading departments and projects in all areas of the pipeline, from novel target identification to early clinical development.

In this time Andy has been involved in a number of therapeutic areas but predominantly inflammation/immunology (osteoarthritis, rheumatoid arthritis, COPD, ischemic/reperfusion injury) and oncology (cell cycle regulation) and more recently CNS and GI. Andy has worked with small molecules, nucleic acids and biologicals in large pharma and the biotech sector and in addition has played a leadership role with successful in- and out-licensing activities.


Current and previous affiliations: General Partner & Scientific Director Eclosion2
January 2014 - to date;
CEO Arisgen SA - January 2014 - to date;
Vice President, Head of Exploratory Projects
Shire Pharmaceuticals January 2011 — December 2013
Vice President of Research
Opsona Therapeutics
November 2008 — December 2010
Associate Director, Respiratory & Inflammation Research
AstraZeneca
January 1998 — October 2008
Team Leader
Johnson & Johnson
October 1995 — December 1997
Forbion Capital Partners
www.forbion.com

(printed by Dr. Kirk Kimmerling, KHG fteBac Technology on Saturday, Dec 5, 2015)

General Information
Forbion Capital Partners
Gooimeer 2-35
1411 DC Naarden
Netherlands

Founded 2007
14 employees (worldwide)
Private ownership

Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, and Munich, Germany. Forbion invests in life sciences companies in drug discovery & development as well as medical device companies addressing substantial unmet medical needs. Forbion’s investment team of ten investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea, PanGenetics, Biovex and Santaris. Current assets under management exceed USD650M, split between five active funds and comprising some 25 promising portfolio companies. Forbion co-manages Biogeneration Ventures, an early stage fund focused on (academic) spin-outs and seed investments in the Netherlands.

Categorization
Main sector Investor
Subsector Venture capital fund

Summary Products / Services / Technologies
No information entered

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products
No information submitted.

Technologies
No information submitted.

Financing Rounds
No information submitted.

Management
Mr. Mulder, Geert-Jan General Partner
Dr. Reithinger, Holger General Partner
Mr. Slootweg, Sander Managing Partner

http://www.partneringone.com/partnering/profile_full.php?id=8008344f$b7wDeECQtfKf&print=1
Delegates

Mr. Boorsma, Marco
Delegate of company: Forbion Capital Partners, Netherlands
Position/Function: Partner

Mr. Mulder, Geert-Jan
Delegate of company: Forbion Capital Partners, Netherlands
Position/Function: General Partner

Mr. Reithinger, Holger
Delegate of company: Forbion Capital Partners, Netherlands
Position/Function: General Partner
Partnering objectives:
- looking for new ground-breaking ideas
Professional background:
- over 15 years of Venture Capital
- product development
- product management
Primary area of expertise:
- Life Science (Rx, Dx, Medtech)
Current and previous affiliations:
- Forbion Capital Partners
- Global Life Science Venture
- 3i
- Technologeholding
- Biometra/Whatman

Mr. Slootweg, Sander
Delegate of company: Forbion Capital Partners, Netherlands
Position/Function: Managing Partner

Prof. van Deventer, San
Delegate of company: Forbion Capital Partners, Netherlands
Position/Function: Managing Partner

Mr. van Osch, Martien
Delegate of company: Forbion Capital Partners, Netherlands
Position/Function: Managing Partner
Gazelle Futures
www.gazellefutures.com/

General Information
Gazelle Futures
9508 Burning Tree Rd
20817 Bethesda, Maryland
United States

Private ownership

An early stage venture capital fund that leverages exclusive, low-cost access to a large portfolio of de-risked invention combined with a proven and award winning “Startup Challenge Accelerator” to rapidly launch new capital efficient companies and grow jobs in undervalued regions

Categorization
Main sector Investor
Subsector Venture capital fund

Summary Products / Services / Technologies
An early stage venture capital fund that leverages exclusive, low-cost access to a large portfolio of de-risked invention combined with a proven and award winning “Startup Challenge Accelerator” to rapidly launch new capital efficient companies and grow jobs in undervalued regions

Financials
Currencies USD
Financing details Minimum of $1MM in valuation; $1.2MM in seed funding for majority equity position

Collaborations and Clients
Partnering strategy/collaborations
Strategic Partners: Pfizer and Medimmune
Collaborators: National Institutes of Health and NASA

Client portfolio
No information entered

Additional Information
Corporate Highlights
Deal Flow Capacity and Rapid & Tangible Results
Performance Focused: Investor goal alignment with strong governance, majority shares along with lower cost lean management system to minimize overhead
Proven Accelerator: Leverages award winning Startup Challenge model, disciplined systematic approach, training & world class industry expert mentorship
Galvanize and Maximize Ecosystem & Receive Recognition: Position undervalued region as a leader for BioMedical research, tech commercialization & industry growth

Anticipated Highlights
About to spin out 40 new companies over the next 4 years; will fund 14 at $1.2MM in seed

Products
No information submitted.
Technologies

No information submitted.

Financing Rounds

No information submitted.

Management

Management
Ms. Truman, Rosemarie Managing Partner

Board of Directors
Dr. Donofrio, Nick Chairman

Delegates

Ms. Truman, Rosemarie

Delegate of company: Gazelle Futures, United States
Position/Function: Managing Partner
Partnering objectives: Syndicate with Series A organizations. We are an early stage venture capital fund that leverages exclusive, low-cost access to a large portfolio of de-risked invention combined with a proven and award winning “Startup Challenge Accelerator” to rapidly launch new capital efficient companies

Professional background: Rosemarie is Chairwoman of the Center for Advancing Innovation (CAI), a Bethesda, MD – based public-private partnership focused on maximizing the commercial potential of high-impact, “gazelle” Federally funded inventions in order to spur entrepreneurship, bolster the economy and positively impact the world. At CAI, Rosemarie conceived of and a novel award-winning challenge accelerator platform that has resulted in the launch of 27 new startups and many prestigious awards and recognition from the White House, Health and Human Services, Wired, Chicago Tribune and more. Rosemarie’s has over 22 years of experience in creating growth breakthroughs for clients which have resulted in more than 100 new products and an unprecedented $21 billion in profits for Fortune 100 clients in the life sciences, aerospace, automotive, Oil & Gas, energy, financial services and high tech industries.

Rosemarie is also the Founder and CEO of Gazelle Futures an early stage venture capital fund that leverages exclusive access to a large portfolio of de-risked, capital efficient, late-stage inventions combined with CAI’s proven and award winning “Startup Challenge Accelerator” to rapidly launch new companies and grow jobs, while increasing the under-valued, capital efficient regions for technology commercialization.

Rosemarie is also an Executive Director in the Founder’s Institute as well as a board member for a number of startups in a variety of software, life sciences, manufacturing, and professional services industries.

Primary area of expertise: Investment banking
Investing and transformation in early stage startups
Early exits generating outsized returns

Current and previous affiliations: Gazelle Futures
The Center for Advancing Innovation
Founder Institute
Goldman Sachs
IBM
PRTM

Deals you have been involved in: 27 deals in cancer and neuroscience
150 deals in other industries
Hanmi Pharmaceutical
www.hanmipharm.com

Hanmi Pharmaceutical is a Korea-based global pharmaceutical company focused on the development and commercialization of new pharmaceutical products. The Company is fully integrated from R&D through manufacturing, marketing and sales with an established presence in Korea as well as China. The Company invests over 20 percent of its sales in R&D and has over 20 programs in clinical development in three main areas: 1) novel long-acting biologics based on the Company's LAPSCOVERY™ platform including weekly insulin, weekly to monthly GLP-1, and their combinations (Quantum Project) in diabetes and obesity; 2) novel targeted agents against cancer and autoimmune disorders; and 3) fixed-dose combination programs. More information on Hanmi is available at www.hanmipharm.com.

Summary Products / Services / Technologies
Hanmi has focused its R&D efforts on several proprietary platform technologies, as well as a number of NCEs, as described below.

a. LAPSCOVERY (Long-Acting Protein/Peptide Discovery) Platform Technology: LAPSCOVERY (Long-Acting Protein/Peptide Discovery) Platform Technology: Hanmi’s LAPSCOVERY technology is the only half-life extension technology currently being developed which overcomes the problems associated with the second generation technologies such as Pegylation, Hyperglycosylation and etc., by minimizing the loss of intrinsic activity and maximizing the half-life (4 to 80 folds of original) of both synthetic and natural target proteins/peptides. This technology has already been applied to various proteins, peptides and enzymes that have shown remarkable results, and currently multiple clinical trials are underway - in the US/EU and Korea. The pipeline includes LAPS-CA-Exendin-4 (efpeglenatide), LAPS-hGH, LAPS-Insulin 115, LAPS-GLP/GCG, LAPS-IFNα, LAPS-FVIIa, LAPS-EPO, etc.

b. Targeted Oncology Program: Hanmi is also developing targeted anticancer therapies that block the action of tumor growth factors using advanced drug discovery technologies such as molecular modeling and combinational chemistry.

One of our lead candidates, HM61713 (Ph 2), is a novel, oral, EGFR mutant-selective inhibitor which specifically targets EGFR T790M. Other promising candidate HM71224 (Ph 1), is an orally active, irreversibly designed BTK inhibitor which potently inhibits BTK signaling in B cell such as p-BTK and p-PLCγ2. HM95573 (Ph 1) is a 2nd generation B-RAF mutant and C-RAF inhibitor targeting B-RAFmut and N-RASmut melanoma which shows excellent synergistic effect with MEK inhibitor in melanoma, NSCLC and mCRC, and excellent in vivo efficacy in B-RAFmut or N-RASmut melanoma xenograft model.

Financials

Collaborations and Clients

Hanmi is dedicated in developing and providing innovative drugs to its customers. In order to achieve this goal, Hanmi is interested in collaborative opportunities including product in-/out-licensing, co-research, co-development, co-promotion, and co-marketing with research institutes, pharmaceutical
companies, and biotech companies both domestic and international. Recent collaborations for LAPScovery technology and targeted oncology programs are:
-Eli Lilly: HM71224 (BTK inhibitor) - WW ex. China, Hong Kong, Taiwan, Korea
-Luye: Poziotinib - China
-Spectrum: LAPs-GCSF - WW ex. Korea, China & Japan
-Spectrum: Poziotinib - WW ex. Korea, China & Japan

Client portfolio
No information entered

Products

BTK inhibitor (HM71224)

Published by Hanmi Pharmaceutical
Product sector Biotech/Pharma
Partnering status Available for out-licensing

Marketing rights available/sought
Main sector Diseases of the blood and blood-forming organs; immune disorders
Subsector n/a
Development phase Phase I
Molecule type Small Molecule/NCE
Mode of administration Oral
Description -BTK inhibitor
-Potent, selective and efficacious in RA models

Clinical trials/clinical strategy KR Ph I Ongoing

Digestive system pipeline Preclinical – P2

Published by Hanmi Pharmaceutical
Product sector Biotech/Pharma
Partnering status Seeking for in-licensing

Marketing rights available/sought
Main sector Digestive system
Subsector n/a

EGFR-mutant Selective Inhibitor (HM61713)

Published by Hanmi Pharmaceutical
Product sector Biotech/Pharma
Partnering status Available for out-licensing

Marketing rights available/sought
Main sector Neoplasms / cancer / oncology
Subsector n/a
Development phase Phase I
Primary market Specialty
Molecule type Small Molecule/NCE
Mode of administration Oral
Description -EGFR mutant selective inhibitor (EMSI)
-Reduced side effects

Clinical trials/clinical strategy KR Ph I Ongoing

HM781-36B (pan-Her inhibitor)

Published by Hanmi Pharmaceutical
Product sector Biotech/Pharma
Partnering status Available for out-licensing

Marketing rights available/sought
Main sector Neoplasms / cancer / oncology
Subsector n/a
Development phase Phase I
Primary market Specialty
Molecule type Small Molecule/NCE
Description HM781-36B (pan-Her + TEC kinase inhibitor)
- Pan-Her Inhibitor against Her-1, Her-2 & Her-4 enzymes
- Potent activity against EGFR mutant cells
- Good PK profiles in animals
- Excellent in vivo efficacy in ErbB expressed cells
- Main toxicity is attributed to Pharmacological effect
- Phase I clinical trial is undergoing in Korea
- Best-in-Class drug against EGFR mutant cells

**IP rights** Patents covering HM781-36B technology are applied worldwide.

### Immune diseases pipeline Preclinical ~ P2

**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Seeking for in-licensing

**Marketing rights available/sought**  
Main sector Diseases of the blood and blood-forming organs; immune disorders  
Subsector n/a

#### LAPS-EPO

**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Available for out-licensing

**Marketing rights available/sought**  
Main sector Diseases of the blood and blood-forming organs; immune disorders  
Subsector Anaemias  
**Development phase** Phase II  
**Primary market** Specialty  
**Molecule type** Natural/Modified Protein  
**Mode of administration** Injectable

**Description** LAPS-EPO (HM10760A): Long-acting EPO candidate  
-Once a month administration  
-Indication: Anemia  
-Phase: US/KR Ph I Completed

LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

**IP rights** Broad patents protecting LAPSCOVERY technology are applied worldwide.

#### LAPS-Exendin analogue

**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Available for out-licensing

**Marketing rights available/sought**  
Main sector Endocrine, nutritional and metabolic diseases  
Subsector Type II/Non-insulin-dependent diabetes mellitus  
**Development phase** Phase II  
**Primary market** Specialty  
**Molecule type** Natural/Modified Protein  
**Mode of administration** Injectable

**Description** LAPS-Exendin (HM11260C): Long-acting Exendin-4 analog  
-Once a month administration  
-Indication: Diabetes  
-Phase: US/KR Ph I & EU Ph II(SAD) Completed  
US Ph II(MAD) Expected

LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

**IP rights** Broad Patents protecting the platform technology (LAPSCOVERY) and the products are applied worldwide.

#### LAPS-FVIIa analog (HM12260A)

**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Available for out-licensing

**Marketing rights available/sought**  
Main sector Diseases of the blood and blood-forming organs; immune disorders  
Subsector Other coagulation defects, purpura and other haemorrhagic conditions  
**Development phase** Lead optimization  
**Primary market** Specialty  
**Molecule type** Natural/Modified Protein  
**Mode of administration** Injectable

**Description** LAPS-FVIIa (HM12260A): Long-acting Factor VIIa analogue

LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

**IP rights** Broad Patents protecting the platform technology (LAPSCOVERY) and the products are applied worldwide.
LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

### LAPS-GCSF analogue

**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Available for out-licensing  

**Marketing rights available/sought**  
- **Main sector**: Diseases of the blood and blood-forming organs; immune disorders  
- **Subsector**: Other diseases of blood and blood-forming organs  
- **Development phase**: Phase II  
- **Primary market**: Specialty  
- **Molecule type**: Natural/Modified Protein  
- **Mode of administration**: Injectable  

**Description** LAPS-GCSF (HM10460A): Long-acting G-CSF candidate  
- Once every three week administration  
- Indication: Neutropenia  
- Phase: US/KR Ph I Completed

LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

**IP rights** Broad patents covering LAPSCOVERY technology and its pipelines are applied worldwide.

### LAPS-hGH

**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Available for out-licensing  

**Marketing rights available/sought**  
- **Main sector**: n/a  
- **Subsector**: n/a  
- **Development phase**: Phase II  
- **Primary market**: Specialty  
- **Molecule type**: Natural/Modified Protein  
- **Mode of administration**: Injectable  

**Description** LAPS-hGH (HM10560A): Long-acting hGH candidate  
- Once a bi-week administration  
- Indication: Growth disorder  
- Phase: KR Ph I Completed / EU Ph II Ongoing

LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

**IP rights** Broad patents covering LAPSCOVERY technology are applied worldwide.

### LAPS-IFN-alpha

**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Available for out-licensing  

**Marketing rights available/sought**  
- **Main sector**: Infectious and parasitic diseases  
- **Subsector**: Hepatitis C  
- **Development phase**: Phase I  
- **Primary market**: Specialty  
- **Molecule type**: Natural/Modified Protein  
- **Mode of administration**: Injectable  

**Description** LAPS-IFNa (HM10660A): Long-acting IFN candidate  
- Once a month administration  
- Indication: Hepatitis virus infection

LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

**IP rights** Broad patents covering LAPSCOVERY technology are applied worldwide.
LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

**IP rights** Broad patents covering LAPSCOVERY technology are applied worldwide.

### LAPS-Insulin
- **Published by** Hanmi Pharmaceutical
- **Product sector** Biotech/Pharma
- **Partnering status** Available for out-licensing
- **Development phase** Preclinical
- **Primary market** Specialty
- **Molecule type** Natural/Modified Protein
- **Mode of administration** Injectable

**Description**
LAPS-Insulin (HM12460B): Long-acting Insulin candidate
- **Indication:** Diabetes
- **Phase:** Preclinical

LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

**IP rights** Broad patents covering LAPSCOVERY technology are applied worldwide.

### LAPS-OXM (Glucagon/GLP-1R Dual Agonist)
- **Published by** Hanmi Pharmaceutical
- **Product sector** Biotech/Pharma
- **Partnering status** Available for out-licensing
- **Development phase** Preclinical
- **Primary market** Specialty
- **Molecule type** Natural/Modified Protein
- **Mode of administration** Injectable

**Description**
LAPS-OXM (HMOXM25): Long-acting Oxyntomodulin (Glucagon/GLP-1R Dual Agonist)
- **Once-weekly administration;** Obesity
- **Long-acting Glucagon/GLP-1R dual agonist with remarkable body weight loss effect**
- **Improvement in lipid metabolism in animal models**
- **No hyperglycemia risk demonstrated in animal models**
- **Favorable therapeutic cost expected from less dosage & dosing frequency**

LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

**IP rights** Broad patents covering LAPSCOVERY technology are applied worldwide.

### Metabolic diseases pipeline Preclinical ~ P2
- **Published by** Hanmi Pharmaceutical
- **Product sector** Biotech/Pharma
- **Partnering status** Seeking for in-licensing

**Marketing rights available/sought**
- **Main sector** Endocrine, nutritional and metabolic diseases
- **Subsector** n/a

### Oncology pipeline Preclinical ~ P2
- **Published by** Hanmi Pharmaceutical
- **Product sector** Biotech/Pharma
- **Partnering status** Seeking for in-licensing

**Marketing rights available/sought**
- **Main sector** Neoplasms / cancer / oncology
- **Subsector** n/a

[Oratecan](http://www.partneringone.com/partnering/profile_full.php?id=8233444f$b79u4igrJpfD6&print=1)
**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Available for out-licensing  
**Marketing rights available/sought**  
**Main sector** Neoplasms / cancer / oncology  
**Subsector** n/a  
**Development phase** Phase II  
**Primary market** Specialty  
**Molecule type** Small Molecule/NCE  
**Mode of administration** Oral  
**Description** OratecanTM (Orally Active Irinotecan)  
- Indication: cancer  
- Phase I Completed, Co-package drug of Irinotecan & HM30181A  

**o Key Features of ORASCOVERY Technology**  
- Anticancer drug + Oral absorption enhancer, HM30181A  
- Universal applicability to oral anticancer drugs  
- Maximizing the safety, efficacy and convenience  
- HM30181A is a P-glycoprotein inhibitor and acts as an oral absorption enhancer.  
- HM30181A itself is not well absorbed but aids the absorption of P-glycoprotein substrates  
- HM30181A does not induce drug-drug interactions  

**IP rights** Patents covering ORASCOVERY technology are applied worldwide.

**Oraxol**  
**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Available for out-licensing  
**Marketing rights available/sought**  
**Main sector** Neoplasms / cancer / oncology  
**Subsector** n/a  
**Development phase** Phase II  
**Primary market** Specialty  
**Molecule type** Small Molecule/NCE  
**Mode of administration** Oral  
**Description** OraxolTM (Orally Active Paclitaxel)  
- Phase II Ongoing, Co-package drug of Paclitaxel & HM30181A  

**o Key Features of ORASCOVERY Technology**  
- Anticancer drug + Oral absorption enhancer, HM30181A  
- Universal applicability to oral anticancer drugs  
- Maximizing the safety, efficacy and convenience  
- HM30181A is a P-glycoprotein inhibitor and acts as an oral absorption enhancer.  
- HM30181A itself is not well absorbed but aids the absorption of P-glycoprotein substrates  
- HM30181A does not induce drug-drug interactions  

**IP rights** Patents covering ORASCOVERY technology are applied worldwide.

**RAF inhibitor (HM95573)**  
**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Available for out-licensing  
**Marketing rights available/sought**  
**Main sector** Neoplasms / cancer / oncology  
**Subsector** n/a  
**Development phase** Lead optimization  
**Primary market** Specialty  
**Molecule type** Small Molecule/NCE  
**Mode of administration** Oral  
**Description** RAF inhibitor  
- Targeting BRAFmt/NRASmt driven cancers  

**Respiratory system pipeline Preclinical – P2**  
**Published by** Hanmi Pharmaceutical  
**Product sector** Biotech/Pharma  
**Partnering status** Seeking for in-licensing  
**Marketing rights available/sought**  
**Main sector** Respiratory system  
**Subsector** n/a

**Technologies**

LAPSCOVERY technology

http://www.partneringone.com/partnering/profile_full.php?id=8233444f$b79u4igrJpfD6&print=1
Published by Hanmi Pharmaceutical
Partnering status Available for out-licensing
Marketing rights available/sought
Sector Drug delivery/formulation technology
Subsector n/a
Description LAPSCOVERY technology exceeds the concept of sustained-release formulation in maintaining the efficacy of biopharmaceuticals for extended periods of time, overcoming the inconvenience of frequent dosing and increasing the value of medication. This technology has already been applied to various proteins, peptides, enzymes have shown very successful results allowing further clinical studies currently underway in USA and EU.

- Key Features of LAPSCOVERY Technology
  - The recombinant carrier of LAPSCOVERY technology confers long-acting properties in protein and peptides in the blood stream
  - The carrier is derived from a safe human protein fragment which does not induce any effector functions such as ADCC or CDC
  - LAPSCOVERY technology enables less frequent treatments than competing products
  - LAPSCOVERY technology can be widely applied to various proteins, peptides, and antibody fragments

Clinical trials/clinical strategy

Current LAPSCOVERY Technology Pipelines
All products below are in clinical trials or late pre-clinical stages, as described below.

- LAPS-GCSF (HM10460A): Long-acting G-CSF candidate/ Once every three week administration / US & KR Ph I Completed
- LAPS-EPO (HM10760A): Long-acting EPO candidate / Once a month administration / US & KR Ph I Completed
- LAPS-hGH (HM10560A): Long-acting hGH candidate / Once bi-weekly administration / KR Ph I Completed, EU Ph 2 Ongoing
- LAPS-IFNa (HM10660A): Long-acting IFN candidate / Once monthly administration / EU Ph I Ongoing
- LAPS-Insulin (HM12460B): Long-acting Insulin candidate / Once weekly administration / Pre-clinical

Partners Not disclosable
IP rights Various patents covering the carrier molecule, carrier conjugates, pharmaceutical composition, and the production methods have been applied worldwide. These patents make LAPSCOVERY technology applicable to various bio-pharmaceuticals.

ORASCOVERY technology
Published by Hanmi Pharmaceutical
Partnering status Available for out-licensing
Marketing rights available/sought
Sector Drug delivery/formulation technology
Subsector n/a
Description Hanmi succeeded in the development of a novel P-glycoprotein inhibitor, HM30181A. Using this molecule, Hanmi discovered ORASCOVERY, the platform technology that enables the development of orally available drugs. Particularly, Oraxol, the orally administered form of Paclitaxel, is about to finish the phase I/II clinical trials and other injected drugs are being the target of ORASCOVERY technology.

- Key Features of ORASCOVERY Technology
  - Anticancer drug + Oral absorption enhancer, HM30181A
  - Universal applicability to oral anticancer drugs
  - Maximizing the safety, efficacy and convenience
  - HM30181A is a P-glycoprotein inhibitor and acts as an oral absorption enhancer.
  - HM30181A itself is not well absorbed but aids the absorption of P-glycoprotein substrates
  - HM30181A does not induce drug-drug interactions

Clinical trials/clinical strategy

Current ORASCOVERY Technology Pipelines
- Oraxol (Oral Paclitaxel): Phase II Ongoing, Co-package drug of Paclitaxel & HM30181A
- Oratecan (Oral irinotecan): Phase I Completed, Co-package drug of irinotecan & HM30181A

Partners Not disclosable
IP rights Patents covering the novel P-glycoprotein inhibitor, the production method, and its pharmaceutical composition have been applied worldwide.

Financing Rounds
Type/Series
Stage/type of financing n/a
Investment USD m 82.00
Valuation USD m n/a
Lead investors
Co-investors
Remarks
Management

Board of Directors
  Mr. Han, Chang-Hee  Senior Vice President & CFO
  Dr. Lee, Gwan Sun  President & CEO
  Mr. Lim, Sung-Ki  Chairman & CEO / Founder
  Mr. Lim, Chong-Yoon  President
  Mr. Min, Kyung-Yoon  Vice Chairman

Delegates

Mr. Jo, Brian
  Delegate of company: Hanmi Pharmaceutical, Korea, South
  Position/Function: Director

Ms. Lee, Jenny
  Delegate of company: Hanmi Pharmaceutical, Korea, South
  Position/Function: Manager

Mr. Lee, Kyungwoo
  Delegate of company: Hanmi Pharmaceutical, Korea, South
  Position/Function: Team leader
JAFCO Co., Ltd
www.jafco.co.jp/english/

General Information
JAFCO Co., Ltd
1-5-1 Otemachi
Chiyoda-ku
100-0004 Tokyo
Japan

Founded 1973
Public

JAFCO is the largest and pioneer of venture capital firm in Japan, founded in 1973. We are focusing on the investment in private companies in life science sector, including biopharmaceuticals, medical devices and platform technologies. JAFCO has invested in more than 60 US and EU life science companies as well as broadly in Japanese biotech companies.

Categorization
Main sector Investor
Subsector Venture capital fund

Summary Products / Services / Technologies
No information entered

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products
No information submitted.

Technologies
No information submitted.

Financing Rounds
No information submitted.
Management

No information submitted.

Delegates

Dr. Harada, Kenji
Delegate of company: JAFCO Co., Ltd, Japan
Division/Department: Lifescience Investment Group
Position/Function: Group Leader

Ms. Toyoda, Miwa
Delegate of company: Jafco, Japan
Position/Function: Principal
JMJ Financial

www.jmjfn.com

General Information

JMJ Financial
501 W. Broadway, Suite 2000
92101 San Diego, California
United States

Private ownership

JMJ Financial is a privately held investment firm that specializes in providing growth and development capital to emerging small cap companies. The firm is founded, managed, and funded by industry pioneer Justin Keener. JMJ is not a broker or finder; the firm invests its own capital into transactions designed to build long term working relationships with a focused group of innovative companies. With over 200 Nasdaq, OTC Markets, NYSE, and OTCBB companies in its portfolio and a long and highly successful track record, JMJ Financial is one of the most active and reliable investors in the space.

Categorization

Main sector Investor
Subsector Private investor

Summary Products / Services / Technologies

No information entered

Financials

Currencies n/a
Financing details No information entered

Collaborations and Clients

Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products

No information submitted.

Technologies

No information submitted.

Financing Rounds

No information submitted.
Management

No information submitted.

Delegates

Mr. Jankowski, Liz
Delegate of company: JMJ Financial, United States
Position/Function: Marketing Manager

Mr. Natan, Eilon
Delegate of company: JMJ Financial, United States
Position/Function: Director of Investments

Mr. Weisman, Sandy
Delegate of company: JMJ Financial, United States
Position/Function: Executive Vice President
Lacerta Bio
lacertabio.com

(printed by Dr. Kirk Kimmerling, KHG fiteBac Technology on Sunday, Dec 6, 2015)

**General Information**

*Lacerta Bio*
132 East 43rd Street
Suite 236
10017 New York, New York
*United States*

*Founded* 2010
1 employees (worldwide) (1 PhDs)
*Private ownership*

Lacerta Bio is a business development & licensing consultancy. We run complete or parallel in- and out-licensing BD processes. We also support internal BD teams with market research, project evaluations, and due diligence.

We also specialize in auditing business development processes, making suggestions on how to improve the efficiency and success of a process.

In 2014, we merged with Ventac Partners, a global consultancy specializing in corporate strategy, business development, and new company formation.

At Biotech Showcase, we are focused on three areas:

1. Out-Licensing a pair of approved diclofenac products, which are backed by head-to-head clinical data demonstrating superior performance.

2. Seeking early-stage investment for a new life science company in formation, which will be focused on the discovery and development of novel compounds for various ophthalmic indications.

3. Introducing Lacerta Bio & Ventac Partners to prospective clients.

**Categorization**

*Main sector* Professional Services and Consulting

*Subsector* Business development

- Deal arranger
- Drug development consulting
- Due diligence
- Management consulting
- Market research
- Technology transfer
- Valuation

**Summary Products / Services / Technologies**

Business Development - We run complete or parallel in- and out-licensing BD&L processes. We specialize in running parallel processes with internal corporate BD teams.

Consulting - We support BD&L processes with market research, project evaluations, and due diligence support.

Company Formation - We seek, evaluate, and create new companies around novel University-based technologies. We are currently raising seed financing for an ophthalmology drug development company.

We also specialize in auditing business development processes, making suggestions on how to improve the efficiency and success of a process.

**Financials**

*Currencies* n/a

*Financing details* No information entered

**Collaborations and Clients**

*Partnering strategy/collaborations*

Our business model involves working closely with clients on a risk-sharing basis.

*Client portfolio*

Current and recently completed projects include:

- Global out-licensing of 2 novel, patented, commercialized products for the treatment of pain (current).

- Fund raising for new ophthalmology company in formation (current).
> Global out-licensing for 4 preclinical assets in oncology, metabolics, osteoporosis, and cardiovascular (completed).

> Competitive Intelligence project supporting a successful transaction

> Out-licensing of portfolio of OTC products (agreement for four products closed)

## Products

### Parenteral Injectable Diclofenac - Patented and Clinically Superior

*Published by* Lacerta Bio  
*Product sector* Biotech/Pharma  
*Partnering status* Available for out-licensing

**Marketing rights available/sought**
- Europe
- USA
- Africa
- South/South East Asia (excl. Japan)
- Australia/New Zealand
- Canada
- Commonwealth of Independent States (CIS)
- Japan
- Middle East
- South America, Central America, Mexico

**Main sector** Musculoskeletal system and connective tissue  
**Subsector** n/a

**Development phase** On the Market  
**Primary market** Specialty  
**Molecule type** Small Molecule/NCE  
**Mode of administration** Injectable

**Description** Lacerta Bio is pleased to represent the opportunity to in-license an innovative, approved parenteral formulation of diclofenac for acute / postoperative pain.

While parenteral diclofenac products are available in a number of markets, our client’s formulation is clinically proven to have superior safety and efficacy characteristics.

Key product benefits over the currently marketed product include:

> Faster onset of action
> Less injection site reactions
> Available as ampule or prefilled syringe
> Free from cyclodextrans and propylene glycol
> Higher concentration, hence lower injection volume
> Intradeltoid administration for convenience and faster pain relief

This injectable diclofenac product is the perfect product for any company seeking to expand their sales in the hospital market.

Conventional parenteral diclofenac products are available in multiple markets around the world under various brands. These products suffer from a number of issues which limit their penetration in the acute pain market:

> Lower concentrations (25 or 37.5 mg/mL) means greater volumes are needed, increasing the probability of local pain upon injection.

> Solubilizers, such as cyclodextrans and propylene glycol, also increase the probability of injection site reactions

> Higher volumes, coupled with use of solubilizers, limits administration to intragluteal or slow intravenous infusion. Intradeltoid injections or IV bolus infusions, while more convenient, are not possible with current products.

> Intragluteal injections cause slower onset of analgesia, and pain relief may not occur when used in obese patients where needle may not reach muscle.

> Intravenous bolus injection impossible with current formulations.

**Our Client’s Product**

Our client has developed, patented, and commercialized an innovative, novel formulation of parenteral diclofenac which solves all of the problems listed previously:

> Available as 75 mg/mL ampule and prefilled syringe, making intramuscular injection a convenient option for physicians and nurses.
> Bolus infusions directly into indwelling lines also an option, as an aqueous formulation is compatible with many different IV fluids.

> No irritating solubilizers in the formulation means lower incidence of thrombophlebitis, resulting in greater patient comfort and satisfaction.

> Higher concentration in aqueous formulation, coupled with intradeltoid injection, results in a stronger (higher Cmax) and faster (shorter Tmax) onset of analgesia.

Our client has achieved this breakthrough through the use of a novel manufacturing process. This process enables the rapid, thorough solubilization of diclofenac in a highly aqueous, highly stable parenteral formulation.

Our client has conducted a head-to-head clinical trial against a commercially-available diclofenac 75 mg/3 ml product. Details on this trial are available upon request.

In summary, our client’s formulation demonstrated superior pain relief, preference by physicians and patients, and lower incidence of thrombophlebitis at the injection site.

Clinical trials/clinical strategy

A partner will likely need to perform a Phase I study for safety, followed by one Phase III versus current brand to show non-inferiority.

Key publications

Clinical trial publications available upon request

Partners

Currently seeking partners Globally.

IP rights

Several patents cover this product; new IP is possible.

Retinal Neuroprotection Company Seeking Financing

Published by Lacerta Bio

Product sector Biotech/Pharma

Partnering status In development

Marketing rights available/sought

Main sector Diseases of the eye

Subsector n/a

Development phase Discovery

Primary market Specialty

Molecule type Small Molecule/NCE

Mode of administration Oral

Description Connexin Therapeutics is currently seeking financing to undertake a connexin inhibitor drug discovery and development program. Work done by our co-founder has demonstrated the following:

• Studies with connexin knock out mice demonstrate retinal cell survival and maintenance under glaucoma and other models of ophthalmic diseases;

• Blockade of connexins using non-specific connexin inhibitors exhibit neuroprotection;

• Retinal cell loss can be kinetically quantified over time, making this the perfect model for evaluating novel retinal neuroprotectants;

• Nonspecific connexin inhibitors demonstrate preservation of both retinal cell structure and function, with the latter quantified via measurements of optic nerve function in normal, diseased, and neuroprotected animal models.

These data and experiences demonstrate the connexin inhibition is a practical, promising approach to preserving retinal cell function under glaucomatous and other ophthalmic disease conditions. However, novel connexin inhibitors are yet to be discovered.

Our plan is to discover and advance a series of novel connexin inhibitors for retinal neuroprotection under different disease conditions. Such compounds could form the basis of early-stage partnerships with multinational pharmaceutical companies.

Seeking Animal Health Opportunities

Published by Lacerta Bio

Product sector Biotech/Pharma

Partnering status Seeking for in-licensing

Marketing rights available/sought

Europe USA

Africa

South/South East Asia (excl. Japan)

Australia/New Zealand

Canada

Commonwealth of Independent States (CIS)

Japan

Middle East

South America, Central America, Mexico

Main sector Cardiovascular
Subsector: n/a  
Development phase: Phase I  
Primary market: Specialty  
Molecule type: Small Molecule/NCE  
Mode of administration: Not yet known  
Description: We are seeking human therapeutics which can be licensed and developed for animal health indications.

Preference for candidates which have already completed Phase I. Earlier-stage assets with a robust, IND-ready package would also be considered.

Potential areas of interest include:

Allergy & Itching
Behavior
Cancer, especially lymphoma
Cardiovascular Disease
Dental Diseases
Diabetes
GI Diseases such as IBD
Infectious Diseases
Kidney Diseases
Obesity
Osteoarthritis
Post-operative Pain
Urinary Tract Disorders

Seeking European Acquisition Opportunities
Published by: Lacerta Bio
Product sector: Medical Technology
Partnering status: Seeking for in-licensing
Marketing rights available/sought: Europe
Sector: Other
Development phase: On the Market
Description: Our client is an US-based investment firm.

They are looking to acquire European products, product portfolios, or even entire companies.

Companies generating Revenue of €50 million or less are preferred, with no restriction on therapeutic area.

Companies generating revenues and with an extensive pipeline would also be considered.

Products or companies must have positive EBITDA.

Pure development-stage companies, service-based companies, or contract manufacturers will not be considered.

Seeking Licensing Opportunities for Chinese Market
Published by: Lacerta Bio
Product sector: Biotech/Pharma
Partnering status: Seeking for in-licensing
Main sector: Cardiovascular
Subsector: n/a
Description: We are seeking US and EU companies who are considering out-licensing their product to a company in China.

From our Shanghai office, we have a deep set of relationships in pharma, biotech, and investors in China who are active seeking "Western" pharmaceutical, biotechnology, diagnostic, and medical device assets.

Topical Diclofenac - Patented and Clinically Superior
Published by: Lacerta Bio
Product sector: Biotech/Pharma
Partnering status: Available for out-licensing
Marketing rights available/sought
Europe
USA
Africa
South/South East Asia (excl. Japan)
Australia/New Zealand
Canada
Commonwealth of Independent States (CIS)
Japan
Middle East
South America, Central America, Mexico

Position/Function:

Partnering objectives:

Main sector
Musculoskeletal system and connective tissue

Subsector
n/a

Development phase
On the Market

Primary market
GP

Molecule type
Small Molecule/NCE

Mode of administration
Topical

Description
Lacerta Bio is pleased to represent the opportunity to in-license an innovative, approved topical formulation of diclofenac for pain.

While topical diclofenac products are available in a number of markets, our client’s formulation is clinically proven to have superior safety and efficacy characteristics.

This topical diclofenac has a number of advantages over available topical diclofenac solutions and gels, making it a perfect product for any company seeking to expand their sales in the pain market.

Key product benefits over marketed products include:

> Clinically-proven faster onset of action
> Superior efficacy versus diclofenac gel
> No DMSO or other penetration enhancers which cause irritation
> Convenient, hands-free, metered dose spray presentation
> Negligible application site reactions in clinical trials

Our client has conducted a head-to-head clinical trial against a commercially-available diclofenac gel. Our client’s formulation demonstrated:

> Faster pain relief
> Improvement in VAS scores of pain intensity
> More patients with pain relief
> Greater physician satisfaction

Clinical trials/clinical strategy
Product is already approved in several countries in Asia. Product will likely require one Phase I trial to prove safety, then a Phase III trial to demonstrate non-inferiority.

Key publications
Clinical trial publications available upon request.

IP rights
Numerous formulation patents either awarded or in process.

Technologies
No information submitted.

Financing Rounds
No information submitted.

Management
Management
Dr. Velez, Carlos Managing Partner

Delegates
Dr. Velez, Carlos N
Delegate of company: Lacerta Bio, United States
Position/Function: Partner, Ventac Partners and Managing Partner, Lacerta Bio
Partnering objectives: At Biotech Showcase 2016, we are out-
Professional background:

Lacerta Bio is a pharmaceutical business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities.

We are especially adept at running efficient international in- and out-licensing processes in parallel with existing, internal BD&L teams. Our approach is seamless and completely transparent. Further, our business model is efficient, and structured towards our mutual success.

Lacerta Bio can also support existing licensing teams with market research, transactional advisory, and other related services.


Our role within the Ventac Partners ecosystem will be focused on growing our consulting practice beyond licensing, as well as seeking early-stage technologies for new company formation in the US.

Specialties: biotech business development, pharmaceutical business development, business development consulting, acquisitions, venture capital, due diligence, pharmaceuticals, biotechnology, life sciences, debt financing, equity financing, merchant banking, investment banking, valuation, due diligence, business planning, consulting.

carlosnvelez@LacertaBio.com
Skype: carlosnvelez


Current and previous affiliations:
Managing Partner
Lacerta Bio | Pharma Biotech Business Development Consulting
October 2010 — Present

Director, Business Development
Penwest Pharmaceuticals
October 2007 — December 2009

Founder and President
Erie Hudson Life Science Consulting
April 2005 — January 2009

Senior Consultant
The Frankel Group
October 1998 — March 2005

Associate
equity4Life
January 2000 — December 2004

Analyst
Genencor International
June 1997 — August 1998

Student
Rochester Institute of Technology
1996 — 1998

Student
University of North Carolina at Chapel Hill
1990 — 1996

Student
Albany College of Pharmacy
1986 — 1990

Deals you have been involved in:
Out-licensing of drug delivery technologies to companies (Otsuka, Cobalt, etc.).
Out-licensing of Opana ER ex-US to Valeant.
Assorted in- and out-licensing projects in various therapeutic areas: oncology, metabolics, pain management, GI, etc.
Various consulting projects supporting internal business development, such as market assessments, competitive intelligence, and BD process audits.
Merck


General Information

Merck
Frankfurter Strasse
64293 Darmstadt
Germany

Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. With over 17,000 employees worldwide, Merck Serono is headquartered in Darmstadt, Germany. In the United States and Canada, EMD Serono operates as a separately incorporated affiliate of Merck Serono.

Partnering is a crucial facet of our organization and is exemplified by many successful collaborations with leading global biotech/pharmaceutical companies in the last two decades. We believe that innovative partnerships in our industry will be the driving force for the next generation of clinically meaningful therapeutics. Acting on our portfolio strategy, our business development executives work in concert with key internal functions (commercial, R&D, etc) to identify the right assets for partnerships. We would like to work with the Pharma and Biotech community to translate the latest innovation into treatments that impact the lives of patients with unmet medical needs.

Currently, we are actively seeking opportunities in the indications mentioned below. Kindly provide the details of your project (eg indication, stage, MoA etc) in your meeting request or visit our website:
http://partnering.merckserono.com

Thanks for your interest in Merck Serono!

Oncology
All Solid & Hematological Tumors

Immunology
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Idiopathic Pulmonary Fibrosis, Severe Asthma, Psoriatic Arthritis, Rheumatoid Arthritis, Systemic Sclerosis, Osteoarthritis (drugs exerting pro-anabolic + anti catabolic effects).

Neurology
Multiple Sclerosis (RRMS, PPMS, SPMS)

Categorization

Main sector Pharma
Subsector Antibodies
Proteins
Small molecule therapeutics
Primary therapeutic area(s)
Neoplasms / cancer / oncology
Diseases of the blood and blood-forming organs; immune disorders
Diseases of the nervous system

Summary Products / Services / Technologies
No information entered

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered
Products

Cardiovascular

Published by Merck
Product sector Biotech/Pharma
Partnering status Seeking for in-licensing
Marketing rights available/sought
Main sector Cardiovascular
Subsector n/a
Development phase On the Market

CDx platform technologies

Published by Merck
Product sector Medical Technology
Partnering status Seeking for in-licensing
Marketing rights available/sought
Sector Diagnostic devices

Diabetes

Published by Merck
Product sector Biotech/Pharma
Partnering status Seeking for in-licensing
Marketing rights available/sought
Main sector Endocrine, nutritional and metabolic diseases
Subsector n/a
Development phase On the Market

Point-of-care devices

Published by Merck
Product sector Medical Technology
Partnering status Seeking for in-licensing
Marketing rights available/sought
Sector Diagnostic devices

Technologies

Coded Libraries

Published by Merck
Partnering status Seeking for in-licensing
Marketing rights available/sought
Sector Discovery Tools
Subsector Chemistry/Molecular Diversity (med chem, combi chem, libraries)
Description Looking for new ways to do "drug screening" - for other technologies enabling to screen more and/or other kinds of molecules against difficult targets. (NOT limited to: DNA encoded libraries, fragment based screening, fragment screening, in silico methods, etc.)

coded libraries

Published by Merck
Partnering status Seeking for in-licensing
Marketing rights available/sought
Sector Discovery Tools
Subsector Chemistry/Molecular Diversity (med chem, combi chem, libraries)
Description DNA-coded libraries or other technologies which can complement classical HTS

functional antibody screening / selection technology

Published by Merck
Partnering status Seeking for in-licensing
Marketing rights available/sought
Sector Discovery Tools
Subsector n/a
Description antibody (or other binder) screening technology platforms based on functional features, not only on binding

Financing Rounds

No information submitted.

Management

http://www.partneringone.com/partnering/profile_full.php?id=820914f5b70hcFVOHfK0&print=1
Management

Dr. Garijo, Belen  Chief Executive Officer
Dr. Herbert, Susan  Head of Global Business Development and Alliance Management
Dr. Rossetti di Valdalbero, Luciano  Head of Global Research & Development

Delegates

Dr. Halle, Joern-Peter
Delegate of company: EMD Serono, Germany
Division/Department: R&D, Healthcare
Position/Function: Head of External Innovation

Dr. Picard, Martin
Delegate of company: Merck KGaA, Germany
Division/Department: External Innovation
Position/Function: Head Search, Evaluation and Due Diligences

Ms. Pickering, Catherine
Delegate of company: Merck, KGaA, Darmstadt, Germany, Switzerland
Position/Function: Head of Oncology & Immuno-Oncology Licensing

Dr. Reitmaier, Birgit
Delegate of company: Merck, Germany
Division/Department: GLBD
Position/Function: Head, Biomarkers and Technology

Dr. Schultes, Christoph
Delegate of company: Merck Serono, a division of Merck KGaA, Darmstadt, Germany
Division/Department: Global Research & Development
Position/Function: Head of Search & Evaluation Oncology at Merck Group
Professional background: Preclinical and clinical R&D, Due Diligence, Search & evaluation
Primary area of expertise: Oncology R&D
Current and previous affiliations: Merck Serono, ELARA Pharmaceuticals

Dr. Stavridi, Eleni
Delegate of company: EMD Serono Research & Development Institute, Inc., United States
Division/Department: External Innovation
Position/Function: Director, Search & Evaluation Immunology

Dr. Vignon, PhD, MBA, Guillaume
Delegate of company: Merck KGaA, Darmstadt, Germany, Switzerland
Division/Department: Global Business Development & Alliance Management
Position/Function: Director Oncology & Immuno-Oncology Licensing

Dr. Weseloh, Rüdiger M.
Delegate of company: EMD, Germany
Division/Department: BD
Position/Function: BD
NSIP LLC
nsipllc.com

General Information
NSIP LLC
795 Route 70 East - Suite E
08053 Marlton, New Jersey
United States

Founded 2010
14 employees (worldwide) (7 PhDs)

Early Stage Investor Healthcare Opportunities. Targeted investments are in the areas of Oncology, Nanotechnologies, Adult Stem Cells, and Bone Marrow Derived Cells that demonstrate potential breakthroughs in the treatment of disease or possess strong advantages over currently marketed products.

The website can be accessed either by:

www.nsipllc.com

or

http://www.ellingtonhealthcarepartners.com

Contact Tel #: 856-396-9393 or 646-450-5587

Categorization
Main sector Investor
Subsector Other
Private investor
Venture capital fund

Summary Products / Services / Technologies
Lead or co-investor, making commitments in multi-stages

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products
No information submitted.

Technologies
http://www.partneringone.com/partnering/profile_full.php?id=8001044f$b772Htkbqy4Y&print=1
No information submitted.

Financing Rounds

No information submitted.

Management

Mr. Duffy, Matt  Managing Member
Dr. Ellenbein, Gerald  Vice Chairman
Mr. Gallagher, Patrick  Managing Member
Dr. Gilbert, David  Managing Member
Mr. Gilbert, Seth  Member
Dr. Glenville, Brian  Member
Dr. Kester, Mark  Member
Mr. Power, John  CFO
Dr. Rosario, Joana  Member
Dr. Sackstein, Robert  Member
Dr. Tether, Anthony "Tony"  Managing Member
Mr. Thompson, Tommy  Chairman
Mr. Ungerleider, Granville  President & Managing Member

Delegates

Mr. Ungerleider, Granville A.

Delegate of company:  NSIP LLC, United States
Position/Function:  Managing Member
Partnering objectives:  Lead and/or Co-investor in areas of Stem Cell, Nanotechnology, and Oncology that clearly demonstrate potential breakthroughs in the treatment of disease or possess competitive advantages over currently-marketed products.
Professional background:  Venture Capitalist, Healthcare Finance, Strategic Advisor
Primary area of expertise:  Finance, Healthcare, Strategic Planning
Current and previous affiliations:  President and Member of the Executive Committee at Ellington Healthcare Asset Management LLC
                                  Managing Member NSIP LLC (the GP for Ellington Healthcare Partners I, L.P.)
Onelife SA
www.onelife.ch

(printed by Dr. Kirk Kimmerling, KHG fiteBac Technology on Saturday, Dec 5, 2015)

General Information
Onelife SA
Cantonale 1
6900 Lugano
Switzerland

Founded 2006
5 employees (worldwide) (4 PhDs)

Onelife is a Swiss Investment and Advisory company managing two separate funds:

1. Onelife Fund is an ethical Life Science sector fund focusing biotech and pharma. The Fund benefits from Onelife unique view and expertise regarding science, demographic changes and in-depth knowledge of the industry.

2. Bright Technologies Fund is a Private Equity Fund investing in companies with large market potential and innovation.

Source of foundation Private

Categorization

Main sector Investor
Subsector Corporate investor
Institutional investor
Private investor
Venture capital fund

Summary Products / Services / Technologies
Onelife pursues a new approach to Life Science and is a recognized thought leader in the field of conjugating profit and sustainable growth for its clients, investors and partners.

Onelife makes a real contribution to the manifold challenges in the Life Science sector capitalizing on its unique industry insights and expertise in three distinct areas:

FINANCE
Onelife Fund is an ethical Life Science sector fund focusing on Biotech and pharma. The Fund benefits from Onelife unique view and expertise regarding science, demographic changes and in-depth knowledge of the industry. Bright Technologies Fund is a Private Equity Fund investing in companies with large market potential and innovation.

ADVISORY
Onelife virtual network and sound experience in the Life Science and Finance sector provides clients such as financial institutions, Life Science companies and family offices with advices for improving evaluation and complex handling of pharmaceutical and biotechnology projects, bio-finance data or investment decision processes.

LICENSES
Onelife supports investors and companies in strategic ventures including in/out license of Life Science projects, acquisition of new technologies and M&As.

Financials

Currencies CHF
Financing details No information entered

Collaborations and Clients

Partnering strategy/collaborations
Direct investment, in-out licensing, development partnership, financial structuring deals.

Client portfolio
No information entered

Products

No information submitted.
Technologies

No information submitted.

Financing Rounds

No information submitted.

Management

Dr. Braglia, Enrico  CEO
Dr. Colnago, Massimo  Equity Analist
Dr. Pericle, Federica  Senior Advisor

Delegates

Mr. Braglia, Enrico

Delegate of company: OneLife SA, Switzerland
Position/Function: CEO
Partnership objectives: Seek Target for Investment for our managed fund. Preferably in EU and already with sales. No basic R&D, services, development stage < ph2.. Yes to Medical Device, OTC, Drug Deliveries.

Professional background: Enrico Braglia, ONELIFE ADVISORS SA founder, received a degree from the Commercial University Bocconi in Milan (Italy). He joined Helsinn Group in 1991, from a previous tenure with Fininvest Financial Services, formerly a Mediaset Company, where he was responsible for the International Treasury and Finance Office. In Helsinn, he served as Managing Director and was responsible for the construction and the management of chemical and pharmaceutical plants in Switzerland and in Ireland. He also lead the business development group in-licensing few new chemical entities. The strategic finance structuring, the administration and the project management of complex international scientific programs including regulatory was also part of his responsibilities. Enrico today manage two funds: (Prospera Senectute Fund - SICAV-SIF & Bright Technologies Fund) investing in Lifescience and High Technologies. OneLife also manage in-out licensing projects, M&D, Strategic Advisory etc. He is involved in several professional and no profit International (UN-PRI, SECA etc.) and Swiss associations.

Specialties: Pharmaceuticals
Biotech
Finance


Dr. Engelmayer, Jose

Delegate of company: OneLife Advisors SA, Switzerland
Position/Function: Equity Research Analyst
ReINNO Capital

(printed by Dr. Kirk Kimmerling, KHG fiteBac Technology on Saturday, Dec 5, 2015)

General Information
ReINNO Capital
3/F., Shun Feng International Centre
182 Queen’s East Road
Hong Kong

Founded 2014
6 employees (worldwide) (5 PhDs)
Private ownership

We are a venture fund dedicated to investing in innovative pharmaceutical or device projects. We have invested in several clinical stage/marketed programs in US for the past year and have brought two products to Asia for registration and commercialization through collaboration with our portfolio companies.

We are interested in getting to know your team and projects to explore potential investment/collaboration opportunities.

Source of foundation Private investors and Funds of Fund

Categorization
Main sector Investor
Subsector Venture capital fund

Summary Products / Services / Technologies
No information entered

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products
No information submitted.

Technologies
No information submitted.
Financing Rounds

No information submitted.

Management

No information submitted.

Delegates

Dr. Yuan, Jenny

Delegate of company: ReINNO Capital, Hong Kong
Position/Function: Managing Partner
Partnering objectives: Looking for investment opportunities of innovation technologies and products in biotech and medical device areas.
Professional background: - 18 years of medical device R&D and BD experiences.
- licensed and developed multiple respiratory, oncology devices and drugs
- Co-founder of a medical device co. in China
- Ex-J&J
San Diego Tech Coast Angels
www.techcoastangels.com

(printed by Dr. Kirk Kimmerling, KHG fiteBac Technology on Saturday, Dec 5, 2015)

General Information
San Diego Tech Coast Angels
12790 El Camino Real
92130 San Diego, California
United States

Private ownership

Tech Coast Angels is a network of over 300 angel investors in Southern California. We focus primarily on Southern California investments, and do not lead investments outside of this area. However, we can make investments in other geographic areas when the deal is led by another angel group that shares its diligence package with us.

Categorization
Main sector Investor
Subsector Business angel
Private investor

Summary Products / Services / Technologies
No information entered

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products
No information submitted.

Technologies
No information submitted.

Financing Rounds
No information submitted.

Management
No information submitted.

Delegates
Mr. Israelsen, Ned

Delegate of company: San Diego Tech Coast Angels, United States
Position/Function: Angel Investor

Partnering objectives: New opportunities for investment; potential applicants for funding by Tech Coast Angels; personal involvement with appropriate startup opportunity

Professional background: Pharmaceutical chemist; IP attorney; angel investor; startup entrepreneur

Primary area of expertise: Pharmaceuticals; medical devices; biotechnology

Current and previous affiliations:
- Tech Coast Angels
- Kalyra Pharmaceuticals (founder; director)
- CardioCreate, Inc. (founder, director)
- John G. Watson Foundation
- Vidacare (acquired by Teleflex)
- Kalyra (founder)
- CardioCreate (founder)
- Actavalon (founder)
- Over 30 Tech Coast Angels companies

Deals you have been involved in:
- Vidacare (acquired by Teleflex)
- Kalyra (founder)
- CardioCreate (founder)
- Actavalon (founder)
- Over 30 Tech Coast Angels companies
Sotio a.s.
www.sotio.com

General Information
Sotio a.s.
Jankovcova 2
17000 Prague
Czech Republic

Founded 2010
300 employees (worldwide)

SOTIO is a biotechnology company and is part of the PPF Group, one of the largest investment groups in Central and Eastern Europe. SOTIO is leading the effort of PPF to build a diverse oncology product pipeline through collaborations, in-licensing, investments and M&A. Currently the biotech portfolio of PPF also includes OriBase Pharma and Cytune Pharma.

We seek innovative therapeutic projects in oncology at late pre-clinical or early clinical stage.

Categorization

Main sector Biotechnology - Therapeutics and Diagnostics
Subsector Antibodies
Cell therapy
Proteins
Small molecules

Primary therapeutic area(s) Neoplasms / cancer / oncology

Summary Products / Services / Technologies

Company Capabilities:
- Global footprint: Biotechnology presence of PPF includes United States, Europe, China and Russia. SOTIO is currently running an international Phase III trial in the United States and Europe as well as multiple Phase II studies, in total in ~20 countries including the US and several EU countries.
- Financial strength: PPF Group is one of the largest investment groups in Central and Eastern Europe, investing across industries including biotechnology, with total assets in excess of EUR 24 billion as of June 2014.
- Focus on partnerships: PPF is currently building its biotechnology product portfolio and seeks to add new exciting oncology assets to its pipeline. PPF and SOTIO are providing expertise and financial resources to each partnership and asset.
- Our track record: PPF together with SOTIO acquired a stake and further invested in life science companies such as OriBase Pharma, Cytune Pharma and Accord Research.
- Areas of expertise: Through its activities in life sciences, PPF/SOTIO has built an integrated development expertise, including late-stage clinical development capabilities and GMP facilities for personalized cellular immunotherapies.

Financials

Currencies n/a
Financing details No information entered

Collaborations and Clients

Partnering strategy/collaborations
SOTIO is leading the effort of PPF to build a diverse oncology product pipeline through collaborations, in-licensing, investments and M&A. We seek innovative therapeutic projects in oncology at late pre-clinical or early clinical stage.

Client portfolio
No information entered

http://www.partneringone.com/partnering/profile_full.php?id=806694f$6b70nGhoOmSlwc&print=1
Products

Seeking partnering opportunities in oncology

Published by Sotio a.s.
Product sector Biotech/Pharma
Partnering status Seeking for in-licensing
Marketing rights available/sought
Main sector Neoplasms / cancer / oncology
Subsector n/a
Description preclinical/early clinical programs

Technologies

No information submitted.

Financing Rounds

No information submitted.

Management

No information submitted.

Delegates

Dr. Prenzel, Norbert

Delegate of company: Sotio a.s., Czech Republic
Position/Function: Head of Business Development and Licensing
Partnering objectives: Seeking in-licensing/partnering/acquisition opportunities in oncology to broaden Sotio’s current development pipeline
Primary area of expertise: BD & Licensing with a particular focus on Oncology
Current and previous affiliations: Previously at U3 Pharma, Staatz BD & Strategy, Micromet, Amgen
Now: Head of BD and Licensing at Sotio
Trifermed
www.trifermed.com

(printed by Dr. Kirk Kimmerling, KHG fiteBac Technology on Sunday, Dec 6, 2015)

General Information
Trifermed
6632 Greene St.
19119 Philadelphia, Pennsylvania
United States

Founded 2002
8 employees (worldwide) (1 PhDs)
Private ownership

Trifermed USA, incorporated in 2016, is the US subsidiary of Trifermed SL, a Contract Business Development provider based in Barcelona, Spain. Out of its Cambridge, MA, and Philadelphia, PA, offices, trifermed provides a suite of comprehensive business development services for the life sciences—from start-ups to well-established multinational organizations (including pharma, biotech, academia, R&D centers, healthcare providers and other related service providers).

Trifermed's experience in Europe, Central America, Canada and Israel—with more than 120 deals successfully implemented over the last decade—makes it the choice company for your partnering needs worldwide.

With its 24/7 cloud-based project management systems and its network of international collaborators, Trifermed is ideally positioned to develop an optimal partnering strategy with you.

Categorization
Main sector Professional Services and Consulting
Subsector Business development

Summary Products / Services / Technologies
Looking for available products in different therapeutic areas for Canada and Spain (licensing and acquisition).
Offering partnering opportunities for:
TBC vaccine
Animal Health Vaccines
TBC Probiotic

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products
A novel treatment for aphthous ulcers and mouth sores
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector n/a
Subsector n/a
Development phase On the Market
Primary market GP
Molecule type Natural/Modified Protein
Mode of administration Transdermal
Description All natural and only triple action treatment for aphthous ulcers:
1. Relieves pain fast
2. Helps stimulate the healing process
3. Reduces swelling
Indications:
1. Mouth ulcers
2. Canker sores
3. Aphthous stomatitis
4. Abrasions to cheeks, lips or tongue due to orthodontic braces or appliances

Registered as Medical Device Class I.

Clinical trials/clinical strategy
Clindamycin
IP rights
Patented formulation

**AL-110 - combination statin treatment for Type 2 Diabetes**

*Published by Trifermed*
*Product sector* Biotech/Pharma
*Partnering status* Available for out-licensing

**Marketing rights available/sought**
*Main sector* Cardiovascular
*Subsector* n/a

**Development phase** NDA
**Mode of administration** Oral
**Description** Combination statin treatment for Type 2 Diabetes: Metformin extended release and Rosuvastatin

**AL-310 - combination statin treatment for Hypertension**

*Published by Trifermed*
*Product sector* Biotech/Pharma
*Partnering status* Available for out-licensing

**Marketing rights available/sought**
*Main sector* Cardiovascular
*Subsector* n/a

**Development phase** NDA
**Description** Combination statin treatment for Hyperlipidemia: Atorvastatin and Ezetemibe

**BioHyaluronan, antiaging line of products**

*Published by Trifermed*
*Product sector* Biotech/Pharma
*Partnering status* Available for out-licensing

**Marketing rights available/sought**
*Main sector* n/a
*Subsector* n/a

**Development phase** NDA
**Description** BioHyaluronan is a line of dermocosmetic products based on a patented combination of Very Low Molecular Weight Hyaluronic Acid and metallic particles that act as carriers. It is the first product to have shown effect on the body's production of own hyaluronic acid. The partner can chose between gold or platinum particles. The indication is antiaging.

Clinical trials/clinical strategy
Clinical studies on effectiveness, safety and toxicity have been already conducted with excellent results.

**Key publications**
Studies can be sent upon request.

**Partners**
The product is ready to be marketed worldwide.

**IP rights**
Patented worldwide PCT/ES2009/000001

**Calves and heifers; Enhancement in Production**

*Published by Trifermed*
*Product sector* Biotech/Pharma
*Partnering status* Available for out-licensing

**Marketing rights available/sought**
*Main sector* Digestive system
*Subsector* n/a

**Development phase** On the Market
**Mode of administration** Oral
**Description** Target species: Calves & heifers, lambs and goatlings / kids

Formulated product rich in polyphenols extracted from natural plants; fine powder to be mixed into milk or milk replacer / was evaluated as "Organic" according to EU directive; Does not require interruption of milk feeding; To be marketed by veterinarians (better diffusion of information), the product offers an added communication tool for distributors to promote other own product lines (complementary or other); In veal units, savings on milk replacers, increased weight gain and reduced costs during pre- and post-weaning. Effect on calves are observed within a short period of time.

Clinical trials/clinical strategy
Better growth assuring improved productivity of heifers (early calving = more milk), higher sale value of males. Feeding to animals at risk of scour. Contributes to a regular digestive transit / motility, has a positive impact on animal's well-being and contributes to the integrated management to improve the well-being of animals.
Ensuring complementarity with distributor’s existing products.
Supports animals in risk of respiratory / digestive problems.

**IP rights** Yes

**COLIPROTEC (E.coli vaccine for animal production)**
*Published by* Trifermed
*Product sector* Biotech/Pharma
*Partnering status* Available for out-licensing

**Marketing rights available/sought**
- **Main sector** Infectious and parasitic diseases
- **Subsector** E.coli
- **Development phase** NDA
- **Primary market** Specialty

**Mode of administration** Oral

**Description** Coliprotec is a live oral vaccine recommended as an aid to preventing post-weaning diarrhea in pigs caused by F4(K88)-positive E. coli bacteria. This is the first live bacterial vaccine for livestock production to have been fully developed and manufactured in Canada.

**Clinical trials/clinical strategy** Approved in Canada, Brasil and Russia.

**Company on sale**
*Published by* Trifermed
*Product sector* Biotech/Pharma
*Partnering status* Available for out-licensing

**Marketing rights available/sought**
- **Main sector** n/a
- **Subsector** n/a

**Description** Company on sale: Import license for Medical Devices in Spain.

**Dental Care Products: Oral Health, Dentist**
*Published by* Trifermed
*Product sector* Biotech/Pharma
*Partnering status* Available for out-licensing

**Marketing rights available/sought**
- **Main sector** n/a
- **Subsector** n/a

**Development phase** On the Market

**Description** We represent a Canadian pharmaceutical that is currently seeking partners to market their products in Europe and Latin America. Four main product lines are Infection Control, Oral Health, Disposables and Hand Care.

**Key publications** Yes

**Partners** Products have CE mark.

**Dermatology / CNS / Oncology / Antiinfectives / Cardiovascular / Gastrointestinal / Gynaecology / Hospital / Pain / etc.**
*Published by* Trifermed
*Product sector* Biotech/Pharma
*Partnering status* Seeking for in-licensing

**Marketing rights available/sought**
- **Main sector** n/a
- **Subsector** n/a

**Development phase** On the Market

**Description** For our clients we search in various therapeutic areas for in-licensing opportunities. Rx or OTC, Medical Devices; Dermatology / CNS / Oncology / Antiinfectives / Cardiovascular / Gastrointestinal / Gynaecology / Hospital / Pain / Pediatrics / Respiratory

**IP rights** No pure generics

**Diclofenac Dual Release**
*Published by* Trifermed
*Product sector* Biotech/Pharma
*Partnering status* Available for out-licensing

**Marketing rights available/sought**
- **Main sector** Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
- **Subsector** Pain

**Development phase** On the Market

**Primary market** GP

**Mode of administration** Oral

**Description** tailor made drug release and plasma levels; both quick onset and sustained action; more efficient and safer therapy of Arthritis and Pain; g.r. / d.r. ensure tmax approx. 1h after intake compared to “Unit Dose” formulations with tmax approx. 2 - 3 hs; g.r. ensures quick onset of action – “The Oral Injection” – for the treatment of acute Arthritis and Pain; s.r. ensures prolonged action for the treatment of chronic Arthritis and Pain;
d.r. divido® ensures quick onset and prolonged action for the treatment of acute and chronic Arthritis and Pain;
improved bioavailability and efficacy;
less inter- and intraindividual plasma level deviations;
prolonged pain relief for 12 - 24 hs;
facilitates therapy decision and treatment;
superior alternative to any available oral Diclofenac formulation;
reduced co-medication

Clinical trials/clinical strategy  Yes
IP rights  Yes

Endocare, skin regenerative product range
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector n/a
Subsector n/a
Development phase On the Market

EXTRARIUS - external eskeletal fixation system for pets
Published by Trifermed
Product sector Medical Technology
Partnering status Available for out-licensing
Marketing rights available/sought
Sector Other
Development phase On the Market
Description www.implantvet.com
IP rights Patented in Europe

Food Supplements: Magnesium, Leg Cramps, Pregnancy
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector n/a
Subsector n/a
Development phase On the Market
Primary market GP
Mode of administration Oral
Description We represent an Israeli pharmaceutical company that has developed a series of innovative food supplements as Magnesium based products & Electrolytes Rehydration Solution Rice Based, which have already been licensed in some European countries.

Gynaecological Opportunities
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector Genitourinary system
Subsector n/a
Development phase On the Market
Description Our italian client has developed an all-natural and topical gel designed for female sexual enhancement and to treat symptoms of Female Sexual Dysfunction. It is the only female sexual enhancement product that contains patented Visnadin. The product is registered as a cosmetic and it is a parabens free formulation!
Partners Meda OTC (Sweden): http://www.sensualbalans.se/
Faran (Greece): http://www.faran.gr/en/cosmetics

Horse Chestnut Seed Extract (HCSE)
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector Cardiovascular
Subsector Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified
Development phase On the Market
Primary market GP
Mode of administration Oral
Description Treatment of Venous Disease approx. one in every 8 adults worldwide suffers from Venous Disease; approx. 5% of patients suffering from Venous Disease are handicapped in their daily work; Venous Disease has developed into a widespread population disease – affecting the quality of life – exhibiting a socio-economic dimension;
Selected herbal products are used for treatment of Venous Disease; HCSE is a leading drug for the oral treatment of Venous Disease; proven mechanism of action – sealing vein membranes – protection against lysosomal enzymes; proven efficacy and tolerance; suitable for long-term therapy; no interactions and contra indications; compared to “Unit Dose” formulations; containing HCSE available in the market, the present principle allows: improved gastro-intestinal tolerance, improved bioavailability and efficacy, less inter-and intraindividual plasma level deviations.

Clinical trials/clinical strategy
Yes
IP rights
Yes

**Infant Milk**

*Published by* Trifermed  
*Product sector* Medical Technology  
*Partnering status* Available for out-licensing

Marketing rights available/sought  
Sector Other  
Development phase On the Market  
Description The product contains the most "state-of-the-art" ingredients aiming to come a step closer to breast milk. 3 different types available.

**Innovative Isotretinoin formulation for the treatment of severe, recalcitrant nodular acne**

*Published by* Trifermed  
*Product sector* Biotech/Pharma  
*Partnering status* Available for out-licensing

Marketing rights available/sought  
Main sector Skin and subcutaneous tissue  
Subsector n/a  
Development phase On the Market  
Primary market Specialty  
Mode of administration Oral  
Description The product uses alternative drug delivery technology and the food in no longer necessary for the drug to be effective, providing more consistent absorption of Isotretionoin under a variety of dietary conditions. Better patient compliance due to a more consistent absorption profile both fed and fasted conditions. Flexibility with dose strengths available.

Clinical trials/clinical strategy
Yes
Partners Rambaxy - USA

**Loop for neurosurgery**

*Published by* Trifermed  
*Product sector* Medical Technology  
*Partnering status* Available for out-licensing

Marketing rights available/sought  
Sector Active implantable devices  
Development phase On the Market  
Description Smart system for securely fixing bone flaps resulting from craniotomies.  
IP rights Patented.

**MD against Nosebleeding**

*Published by* Trifermed  
*Product sector* Biotech/Pharma  
*Partnering status* Available for out-licensing

Marketing rights available/sought  
Main sector Respiratory system  
Subsector Other diseases of upper respiratory tract  
Development phase On the Market  
Description A new and unique treatment of nosebleeds, CE approved medical device class I and filed for patent. This product presents significant advantages compared to current treatments and additional benefits that address unmet needs of customers from this growing ENT niche market. The product is produced by a Swedish pharmaceutical company focused on the area of nasal disorder which has already successfully introduced its products in other European markets and now is looking for partners interested in this opportunity.  
Key publications A randomised, double-blind, multicentre clinical study was performed 1994 on 68 patients with nosebleed (epistaxis) comparing placebo gel with tranexamic acid gel – a drug inhibiting fibrinolysis. (Tibbelin A et al. ORL 1995;57:207-209)  
Partners Already licensed in Spain, Greece, Canada and Mexico.  
IP rights Patented.

**Medical Device for facilitating the process of enteral nutrition**

*Published by* Trifermed  
*Product sector* Medical Technology  
*Partnering status* Available for out-licensing
Marketing rights available/sought
Sector Other
Description A Medical Device that makes life easier for people on enteral nutrition. Enhances autonomy of the patient and reduces times that the patient has to be assisted.

Medical devices in Gastroenterology and Ophthalmology
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector Diseases of the eye
Subsector n/a
Development phase On the Market
Description All products available for Mexico. For other countries, availability has to be checked for each individual product. Please contact us for more information.

Mycobacterium fortuitum - probiotic for tbc
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector Infectious and parasitic diseases
Subsector Tuberculosis
Development phase NDA
Primary market GP
Mode of administration Oral
Description From a environmental mycobacteria, the Mycobacterium fortuitum, which is present in the water we drink and we can also find it as part of the intestinal flora (so it is a probiotic), Manremyc developed the Nyaditum Resae, which is manufactured from Mycobacterium fortuitum, strain Manresa (Spain), died by hot. Its mechanism of action is based on maintaining an inflammatory response that in human lung it is enough to let the encapsulation system of the inflammatory injuries, avoiding its union to a cavitated injury which is characteristic of the lung tuberculosis disease. To obtain this inflammatory response the regulatory T cells are grown by the effect of the immune system to the Mycobacterium.
IP rights WO2013/186409 A1
Description Inactivated Mycobacteria for oral use to decrease the risk of active Tuberculosis.

Oral fish vaccine
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector Infectious and parasitic diseases
Subsector n/a
Development phase NDA
Description Oral immunostimulant for aquaculture, patented and totally innovative.

OTC Line (European CTD Dossiers)
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector n/a
Subsector n/a
Description We represent a Spanish pharmaceutical company that has developed a series of OTC dossiers in the therapeutic areas of Cough & Cold, Pain Management, Antimucolytic, Antitussive, Nasal Decongestant and Dizziness.

Pasteurella Vaccine for Animal Health / Production
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector Infectious and parasitic diseases
Subsector Other intestinal infectious diseases
Development phase Preclinical
Primary market Specialty
Mode of administration Not yet known
Description An inactivated vaccine obtained from a proprietary, genetically modified Pasteurella multocida strain. The key aspect of the invention is the modification of a master gene in the regulation of the expression of iron-
dependant proteins in Bacteria. The resulting stabilized strain developed spontaneous mutation that contribute to a very broad and potent immunogenicity profile, able to recognize different strains within the species and different species within the genus (P. multocida, M. haemolytica, H. parasuis, H. influenza and Actinobacillus strains).

**IP rights** Worldwide Patent (main markets)

**Radiocare - Oncology supportive care (Radiotherapy)**

*Published by* Trifermed

*Product sector* Biotech/Pharma

*Partnering status* Available for out-licensing

*Marketing rights available/sought*

- **Main sector** Skin and subcutaneous tissue
- **Subsector** Radiation-related disorders of the skin and subcutaneous tissue

*Development phase* On the Market

*Mode of administration* Topical

*Description* An innovative formulation to prevent and treat acute and chronic radiodermatitis. This cream is based on 4% of CAS (Cryptophalus aspersa's Secretion) a natural component with powerful regenerating and antioxidant properties that helps protecting the skin from external aggression. Its registration status will depend on the regulatory system of each country.

*Key publications*

Conclusions: It is as efficient or even better than standard treatment (camomille water and corticosteroids). Preventive treatment is significantly more beneficial regarding evolution of radiodermatitis. It had no side effects and were well tolerated. Radiocare® has been evaluated by both patients and investigators, being more satisfactory than standard treatments.

Conclusions: Significant clinical improvement occurs in the major discomfort variables (erythema, pruritus and burning) within one week.

*Partners* Already licensed in Spain, Greece, Venezuela, South Korea.

*IP rights* US, European and Worldwide patents of Radiocare: “Therapeutic and cosmetic compositions for treatment of skin”.

**Range of Ear, Nose and Throat products (Medical devices)**

*Published by* Trifermed

*Product sector* Biotech/Pharma

*Partnering status* Available for out-licensing

*Marketing rights available/sought*

- **Main sector** Respiratory system
- **Subsector** n/a

*Development phase* On the Market

*Description* Our israelian client has developed a full ENT range intended for the nasal, throat and ear cleansing and hygiene. All the products are classified as medical devices and some of them have Clinical Trials and patent applications. Moreover, those products has already been licensed in some European countries.

*Clinical trials/clinical strategy* Yes

**RUTI (tbc vaccine)**

*Published by* Trifermed

*Product sector* Biotech/Pharma

*Partnering status* Available for out-licensing

*Marketing rights available/sought*

- **Main sector** Infectious and parasitic diseases
- **Subsector** Tuberculosis

*Development phase* Phase II

*Primary market* GP

*Description* RUTI®, an inactivated vaccine first in class for the tuberculosis treatment, developed by Archivel Farma (a Spanish-based biotech company, www.archivelfarma.com) in collaboration with the Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol · IGTP (Badalona, Spain), has successfully reached the end of a Phase II clinical trial (final report May 2012, paper February 2014).

*Clinical trials/clinical strategy* RUTI® has been exposed to 24 individuals (phase I, Spain) and 96 individuals (phase II, South Africa). Phase II shows that RUTI® elicits a poly-antigenic specific immune response after a one-month isoniazid (INH) treatment, even in immunosuppressed individuals such as HIV+ patients with latent tuberculosis infection. The single subcutaneous administration 25µg dose has proved to be a good safety and potent dose regime.

*IP rights* WO2005/042013

Immunotherapic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals.

WO2008/053055

Prophylactic tuberculosis vaccine

WO2010/031883

Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis.

WO2012/093137
Liposome formulation suitable for treating or preventing tuberculosis.

WO2013/104943
MTB-C vaccine against asthma.

Selenase
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector Infectious and parasitic diseases
Subsector n/a
Development phase On the Market
Primary market Specialty
Mode of administration Injectable
Description

Clinical trials/clinical strategy
• Extensive package of clinical data available.
• Recent studies showed significant benefit by selenium therapy.
• Further clinical trials on-going.
• German and European university hospitals are using selenase® for its efficacy and clinical benefit.

Partners
Existing Registration and Marketing authorization
• For: selenase® as injection and/or oral solution with several dosages.
• Where: e.g. Argentina, Austria, Brazil, Czech Republic, Germany, Hungary, Ireland, Italy, Luxemburg, Netherlands, Portugal, Russia, Slovakia, South Korea, Switzerland, Turkey, Ukraine, UK.

IP rights
• Patent on API manufacturing: sodium selenite pentahydrate (GMP).
• Application patents on selenium in sepsis and selenium in oncology.
• Trademark “selenase” protected in most parts of the world, also in the USA.

Skin Care cosmetics for babies and children
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector Skin and subcutaneous tissue
Subsector n/a
Development phase On the Market
Description
The product line is especially designed and studies for the various needs of the babies and children and fully complies with the specifications for products of the kind.

SSAO Inhibitor - diabetic vascular disease
Published by Trifermed
Product sector Biotech/Pharma
Partnering status Available for out-licensing
Marketing rights available/sought
Main sector Cardiovascular
Subsector n/a
Development phase Preclinical
Molecule type Small Molecule/NCE
Mode of administration Oral
Description
An inhibitor of a novel vascular amine oxidase (SSAO) to meet unmet medical need in diabetic nephropathy, neuropathy, restenosis;
First-in-class oral drug for daily dosing. Disease Area: First line therapy for the treatment and prevention of glomerulosclerosis in diabetic individuals presenting with microalbuminuria. Neuropathy, restenosis and atherosclerosis are alternate indications. Target validation: High quality in vivo data demonstrating that SSAO is a target to treat vasculopathy and associated diabetic complications such as nephropathy
Partners
Searching for transfer to a partner or co-development.
IP rights Patented

Superior Treatment for varicose veins
Published by Trifermed
Product sector Medical Technology
Partnering status In development
Marketing rights available/sought
Sector Anaesthetic and respiratory devices
Development phase Development
Description: Our Israeli client has fully developed a challenging, easy to use, clinically proven device that solves a problem affecting millions of patients worldwide regarding varicose veins. All veins are extracted through 1-3 incisions given superior aesthetic result and less tissue damage. The device has achieved the design freeze. It has an strong patent protection and it's FDA approved.

Clinical trials/clinical strategy: Yes

Partners: Our client is seeking for investors and shareholders.

IP rights: Yes

Synthetic Bone graft (SBG)
Published by: Trifermed
Product sector: Medical Technology
Partnering status: Available for out-licensing
Marketing rights available/sought: Other
Development phase: On the Market

Description: A new generation synthetic bone graft (SBG) scaffold designed to replace the autograft procedure. It is made from pure synthetic hydroxyapatite (HA) and is fully resorbable. It has a complex porous structure including micropores, midipores and macropores in order to integrate with new bone formation down to the cellular level.

Topical OTC line of 5 natural bio-active therapeutic ointments
Published by: Trifermed
Product sector: Biotech/Pharma
Partnering status: Available for out-licensing
Marketing rights available/sought: Other
Main sector: Skin and subcutaneous tissue
Subsector: n/a
Development phase: On the Market

Description: The topical OTC line is divided into three main groups:
- Haemorrhoids treatment;
- Damaged skin; dermatitis, acne, diaper rash;
- Coughs, colds, nasal and chest congestion.
Available for all Europe, Latin America and Israel. Unique Science based Ointments, Petro-chemical & paraben free; Peta's: cruelty free company program; Vegan: no animal testing.

Tramadol
Published by: Trifermed
Product sector: Biotech/Pharma
Partnering status: Available for out-licensing
Marketing rights available/sought: Other
Main sector: Musculoskeletal system and connective tissue
Subsector: n/a
Development phase: On the Market

Description: Indication: moderate to moderately-severe pain.
Competitive Advantage: Fast onset and extended release combined.

Clinical trials/clinical strategy: Yes

Partners: Vertical Pharmaceuticals - USA
Medical Futures - Canada

IP rights: Patented in USA and Canada

Unique endoscopy devices range
Published by: Trifermed
Product sector: Medical Technology
Partnering status: Available for out-licensing
Marketing rights available/sought: Other
Development phase: On the Market

Description: Second generation Biopsy Cap Valve; First Single Use Red Suction Button for any kind of Endoscopes; Enzyme Free Sink Shot for cleaning endoscope at cleaning area; Gastroenterology (GI) Kit (single use endoscopy kit containing a scope clean, gauze, suction tubes, gauze, aqua jelly and impermeable bag to carry the endoscope to cleaning area)

VETERINARY: Coliprotec, a live oral vaccine against E.Coli associated post-weaning diarrhea in piglets.
Published by: Trifermed
Product sector: Biotech/Pharma
Partnering status: Available for out-licensing
Marketing rights available/sought: Other
Main sector: Digestive system
Subsector: n/a
Development phase: On the Market
Mode of administration: Oral

Description: Coliprotect went on sale in Canada in December 2007 / In Brazil in 2011. Meanwhile, steps have been taken in order to seek regulatory approval for the US, Mexican and European markets.
Clinical trials/clinical strategy Clinical Trials have been done in Canada. In Europe on-going.

Key publications

Partners In order to finance the European project, Prevtec is seeking investment to complete an open round. Commercial Partnerships are under discussion.

IP rights Patented worldwide.

Xilonibsa, anesthetic urethral gel

Published by Trifermed

Product sector Biotech/Pharma

Partnering status Available for out-licensing

Marketing rights available/sought

Main sector Genitourinary system

Subsector n/a

Description Xilonibsa is a lidocaine chlorhydrate gel with a very innovative design. The presentation is an urological solution with high superficial anesthetic effect and low toxicity. The innovative design is an exclusive polypropylene applicator in an accordion form that improves the container handling at the time of application. Developed Prescription medication with an updated dossier. Behind Xilonibsa there is a complete line of anethetics if a company wished to build up a line of Hospital products.

α2β1 Integrin Inhibitors - Treatment of thrombosis, inflammation or cancer

Published by Trifermed

Product sector Biotech/Pharma

Partnering status Available for out-licensing

Marketing rights available/sought

Main sector n/a

Subsector n/a

Development phase Preclinical

Molecule type Small Molecule/NCE

Description Thrombosis: α2β1 integrin is a major collagen receptor on the surface of platelets, Adhesion of platelets to collagen via α2β1 integrin is the triggering step in thrombus formation at the site of endothelial damage; A high level of α2β1 integrin on platelets has been shown to be an independent significant risk factor for thromboembolic diseases; Inflammation: α2β1 integrin is used by leukocytes for attachment and extravasation from the vasculature into peripheral tissues (inflammatory sites); Pathological accumulation of leukocytes in tissues is a main mechanism behind many inflammatory diseases; Cancer: α2β1 integrin expression is upregulated in many types of cells when being transformed from normal to tumor cells; Cancer cells use integrins when moving through tissues and forming metastases; Induced expression of collagen receptor integrins may mediate driven angiogenesis in cancer

Partners Searching for transfer to a partner or co-development.

IP rights Patented

Technologies

Golden Hyaluronan (Osteoarthritist solutions with hyaluronic acid)

Published by Trifermed

Partnering status Available for out-licensing

Marketing rights available/sought

Sector Drug delivery/formulation technology

Subsector Controlled Release

Description Golden Hyaluronan is a patented combination of High Molecular Weight Hyaluronic Acid with gold particles that represents an important advance for joint diseases treatment, where hyaluronic acid's intraarticular stability is substantially increased.

Key publications Studies can be sent upon request.

Partners The partner can in-license the technology and carry out its own development.

IP rights Golden Hyaluronan is a patented technology with great potential for joint diseases indications. Patented worldwide PCT/ES2009/000001

Innovative genomic analysis methods

Published by Trifermed

Partnering status Available for out-licensing

Marketing rights available/sought

Sector Discovery Tools

Subsector n/a

Description Our client strategy is to bringing together THE BEST OF BIOMATERIALS and INNOVATIVE GENOMIC ANALYSIS METHODS to the world of genomic discovery, diagnostics and drug development.

Our client capabilities combine its OWN RESEARCH PROGRAMS together with a PLATFORM OF SERVICES for public, private, academic and corporate institutions.
**Field of use restriction**

- **BIOBANK:** The largest biobank in Spain, based on a network of more than 25 Hospitals and Institutions; with more than 20,000 human samples, represent many of the most relevant diseases.
- **DISCOVERY RESEARCH:** Genomic study capability range from project design and patient recruitment to the full execution of large, complex studies.
- **HFCC DATA ANALYSIS:** Based on patented technology aptly named "hypothesis-free clinical cloning". HFCC is a genome analysis tool that enables rapid marker identification and confident decision-making about which markers to pursue further. It is the unique patented technology able to perform two-locus (multi-locus) genome analysis.

**Clinical trials/clinical strategy**

Investigation focus:
- Alzheimer Disease
- Cancer
- Cardiovascular
- Metabolism
- Menopause

**Partners**
- INTERNATIONAL INVESTIGATION PUBLIC CENTERS: Japanese Foundation for Cancer Research, National Cancer Center (Japan), University of Leicester (Germany), Uniwersytet Jagiellonski Krakow (Poland).
- BIOTECH COMPANIES & MEDICAL PROVIDERS: Johnson&Johnson, DNA Print Genomics Inc., Bioserve Biotechnologies, Progenika Biopharma, S.A., Cross Road Biotech, Oy Jurilab Ltd, ...

**IP rights**
- PCT/ES2005/070073 (P200402737)
- PCT/EP2007/050264 (HFCC)
- P200502225
- P200602692

**Technique for bonding oxide ceramics**

*Published by Trifermed*

**Partnering status** Available for out-licensing

**Marketing rights available/sought** n/a

**Subsector** n/a

**Description** Can be easily be applied on currently used additive technologies without affecting the bulk, without loss of precision, and at low cost. Materials:
- Aluminum oxide, Zirconium dioxide (Y-TZP)

**Reconstructions:**
- "Maryland bridges, Crowns, Veneers

**For:**
- Retention, Esthetics, Reinforcement

**Key publications** Yes

**IP rights** Patented

**Financing Rounds**

*No information submitted.*

**Management**

Mr. Bateman, Roy  Director Latin America
Dr. Fernandez, Marta  Director South Europe
Mr. Henriques, Antonio  Director Trifermed Sao Paolo
Dr. Nascimento, Clara  Director America
Ms. Ortega, Maria  Business Unit Manager
Ms. Reid, Stephanie  Business Unit Manager
Mr. Schäfer, Mario  Director North Europe
Dr. Taroncher-Oldenburg, Gaspar  VP
Dr. Trilla, Sergi  CEO

**Delegates**

Dr. Taroncher-Oldenburg, Gaspar

*Delegate of company:* Trifermed, United States

*Position/Function:* VP
TVM Life Science

www.tvm-lifescience.com

TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 25-years of transatlantic investment track record and in excess of US$1.1bn under management. The Life Science Investment Group’s mission is to invest in the development of exciting early stage drug candidates and companies in the medical field that are or aspire to be innovative leaders in their market segment. Since 1984, TVM Capital Life Science made 116 investments in life science companies in Europe and the United States and exited from 85 companies, including 41 initial public offerings on the NASDAQ, and the London, Frankfurt, Zurich and Vienna Stock Exchanges and 25 trade sales and mergers. The Life Science team combines long-standing international investment and company building experience with their track record of dedicated board work, extensive global networks in the world of life science research and product development and a direct knowledge of the local markets. TVM Capital Life Science currently invests from its 7th fund generation, TVM Life Science Ventures VII, with an integrated team of investment professionals based in in Montreal and Munich.

More information: www.tvm-lifescience.com or twitter: tvmcapital

Categorization

Main sector  Investor
Subsector  Venture capital fund

Summary Products / Services / Technologies

No information entered

Financials

Currencies  USD
Financing details  No information entered

Collaborations and Clients

Partnering strategy/collaborations  No information entered
Client portfolio  No information entered

Products

No information submitted.

Technologies

No information submitted.

Financing Rounds

No information submitted.

Management

Dr. Birner, Hubert  Managing Partner
Dr. Schuehsler, Helmut  Managing Partner
Delegates
Dr. Riviere, Marc

Delegate of company: TVM Life Science, Canada
Position/Function: General Partner
Professional background: MD
Primary area of expertise: Drug development
Current and previous affiliations: TVM, Aptalis, Caprion, Xenon, Bioniche, Ae terra, Quintiles, Benefit
Ventureast
www.ventureast.net

(printed by Dr. Kirk Kimmerling, KHG fitBac Technology on Saturday, Dec 5, 2015)

**General Information**
Ventureast
Ventureast Plaza, Financial District
Gachi Bowli
500032 Hyderabad
India

Founded 1995
20 employees (worldwide)
Private ownership

Pioneering early stage VC investor with focus on healthcare and life sciences sectors. While we invest globally, we do seek an India angle in the business

**Categorization**
Main sector Investor
Subsector Institutional investor

**Summary Products / Services / Technologies**
VC investor

**Financials**
Currencies n/a
Financing details No information entered

**Collaborations and Clients**
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

**Products**
No information submitted.

**Technologies**
No information submitted.

**Financing Rounds**
No information submitted.

**Management**
No information submitted.

**Delegates**
Mr. Samavedam, Jagannath
Delegate of company: Ventureast, India
Division/Department: Investments
Position/Function: Senior Principal
Partnering objectives: Meet startups in biotech/medtech space. Get up to date with global trends in healthcare / life sciences investing.
Professional background: VC investor with over 20 years experience in working with early stage companies
Primary area of expertise: Investing
Deals you have been involved in: Evolva; Diabetomics; Mardil; Melior and several Indian life sciences companies
Versant Ventures

www.versantventures.com

Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm's founding in 1999, nearly 40 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com.

Categorization

Main sector Investor
Subsector Venture capital fund

Summary Products / Services / Technologies

No information entered

Financials

Currencies n/a
Financing details No information entered

Collaborations and Clients

Parting strategy/collaborations
No information entered
Client portfolio
No information entered

Products

Seeking preclinical mAbs

Published by Versant Ventures
Product sector Biotech/Pharma
Parting status Seeking for in-licensing
Marketing rights available/sought
Main sector Neoplasms / cancer / oncology
Subsector n/a
Development phase Preclinical
Molecule type Antibody

Technologies

No information submitted.

Financing Rounds

No information submitted.

Management
No information submitted.

Delegates

Dr. Larson, Stefan

Delegate of company: Versant Ventures, Canada
Position/Function: Entrepreneur-in-Residence
Partnering objectives: Interested in meeting companies with early-stage therapeutic antibodies - discovery stage through to early clinical.
Professional background:
- Entrepreneur-in-Residence, Versant Ventures
- President, Blueline Bioscience
- CEO, Northern Biologics
Primary area of expertise: Antibody therapeutics
Yangtze River Pharmaceutical Group
yangtzeriver.com

(printed by Dr. Kirk Kimmerling, KHG fiteBac Technology on Sunday, Dec 6, 2015)

General Information
Yangtze River Pharmaceutical Group
Bld 8, Lane 67, Libing Road,
Zhangjiang High Tech Park
201203 Shanghai, Shanghai
China

Founded 1971
10000 employees (worldwide)

Yangtze River Pharmaceutical Group (YRPG) is a fully-integrated pharmaceutical company in China. The group achieved 7.19 billion USD for revenue in 2014 with CAGR of 19% for the past 10 years.

YRPG has 24 branch companies with over 10,000 employees across China. More than 130 products have been registered and marketed in China, covering 10 major therapeutic areas with great emphasis in the fields of Infection, CNS, GI, Respiratory, CNS and Oncology.

YRPG is actively seeking partners worldwide for innovative drug development, and would like to out-license the rights outside of China of two in house NCE projects in CNS and oncology therapeutic areas. YRPG is also seeking in-licensing opportunities and corporate alliances with major pharmaceutical companies worldwide.

Categorization
Main sector Pharma
Subsector Generics
Primary therapeutic area(s)
- Infectious and parasitic diseases
- Neoplasms / cancer / oncology
- Endocrine, nutritional and metabolic diseases
- Diseases of the nervous system
- Cardiovascular
- Respiratory system
- Digestive system

Summary Products / Services / Technologies
YRPG is actively seeking partners worldwide for innovative drug development, and would like to out-license the rights outside of China of two in house NCE projects in CNS and oncology therapeutic areas.

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
No information entered
Client portfolio
No information entered

Products
NCE for Central Nervous System Disease
Published by Yangtze River Pharmaceutical Group

http://www.partneringone.com/partnering/profile_full.php?id=8188944f5b711fSeBnz5g&print=1
Product sector: Biotech/Pharma  
Partnering status: Available for out-licensing  
Marketing rights available/sought:  
- Europe  
  - USA  
  - Africa  
  - South/South East Asia (excl. Japan)  
  - Australia/New Zealand  
  - Canada  
  - Commonwealth of Independent States (CIS)  
  - Japan  
  - Middle East  
  - South America, Central America, Mexico  
- Asia  
  - North East Asia  
  - South East Asia  
  - India  
  - Australia/New Zealand  
  - Canada  
  - Japan  
  - Middle East  
  - South East Asia  
  - South East Asia (excl. Japan)  
  - South East Asia (excl. Japan)  
  - South East Asia (excl. Japan)  
Main sector: Diseases of the nervous system  
Subsector: n/a  
Development phase: Preclinical  
Molecule type: Small Molecule/NCE  
Mode of administration: Oral  
Description: The compound is a new chemical entity for treatment of insomnia. It is now at late stage of pre-clinical study and will be ready for IND by early 2016.  
Clinical trials/clinical strategy: Phase I planned for 2016  
IP rights: Yangtze River  

NCE in Oncology  
Published by: Yangtze River Pharmaceutical Group  
Product sector: Biotech/Pharma  
Partnering status: Available for out-licensing  
Marketing rights available/sought:  
- Europe  
  - USA  
  - Africa  
  - South/South East Asia (excl. Japan)  
  - Australia/New Zealand  
  - Canada  
  - Commonwealth of Independent States (CIS)  
  - Japan  
  - Middle East  
  - South America, Central America, Mexico  
- Asia  
  - North East Asia  
  - South East Asia  
  - India  
  - Australia/New Zealand  
  - Canada  
  - Japan  
  - Middle East  
  - South East Asia  
  - South East Asia (excl. Japan)  
  - South East Asia (excl. Japan)  
  - South East Asia (excl. Japan)  
Main sector: Neoplasms / cancer / oncology  
Subsector: Non-small cell lung cancer  
Development phase: Preclinical  
Molecule type: Small Molecule/NCE  
Mode of administration: Oral  
Description: The compound is a new chemical entity for the treatment of non-small cell lung cancer. It is now at late stage of pre-clinical study and will be ready for IND by early 2016.  
Clinical trials/clinical strategy: Phase I planned for 2016  
IP rights: Yangtze River  

Open for discussion: Cardiovascular  
Published by: Yangtze River Pharmaceutical Group  
Product sector: Biotech/Pharma  
Partnering status: Seeking for in-licensing  
Marketing rights available/sought:  
- Main sector: Cardiovascular  
  - Subsector: n/a  

Open for discussion: CNS  
Published by: Yangtze River Pharmaceutical Group  
Product sector: Biotech/Pharma  
Partnering status: Seeking for in-licensing  
Marketing rights available/sought:  
- Main sector: Diseases of the nervous system  
  - Subsector: n/a  

Open for discussion: Digestive System  
Published by: Yangtze River Pharmaceutical Group  
Product sector: Biotech/Pharma  
Partnering status: Seeking for in-licensing  
Marketing rights available/sought:  
- Main sector: Digestive system  
  - Subsector: n/a  

Open for discussion: Oncology  
Published by: Yangtze River Pharmaceutical Group  
Product sector: Biotech/Pharma
Technologies

No information submitted.

Financing Rounds

No information submitted.

Management

No information submitted.

Delegates

Dr. Lan, Jiong

Delegate of company: Yangtze River Pharmaceutical Group, China
Position/Function: General Manager

Ms. Zhang, Jingya

Delegate of company: Yangtze River Pharmaceutical Group, China
Position/Function: Business Development Manager
Yorkville Advisors

www.yorkvilleadvisors.com

(printed by Dr. Kirk Kimmerling, KHG fiteBac Technology on Saturday, Dec 5, 2015)

General Information
Yorkville Advisors
1012 springfield ave
07092 mountainside, New Jersey
United States

Founded 2001
20 employees (worldwide)
Private ownership

Yorkville Advisors is an investment fund with offices in New Jersey (USA) and in London. Its Healthcare Investment Group is focused on investing in all areas of Life Sciences (Therapeutics, Diagnostics, Devices as well as in Services). Companies seeking investment must be publicly listed and traded on a US, European or Australian stock exchanges.

Current and Past Investments:
Sensorion (France)
Novacyt (UK / France)
4SC (Germany)
Epigenomics (Germany)
Hybrigenics (France)
Genfit SA (France)
Evolva Holdings (Switzerland)
Santhera Pharmaceuticals (Switzerland)
Physiomics PLC (UK)
Saruem PLC (UK)
Newrwon Pharmaceuticals (Italy/Switzerland)
EntreMed (USA)
DMedical (Israel)
ItN Nanovation (Germany)
BiondVax (Israel)
Oasmia (Sweden)
Medicago (Canada)
Allon Therapeutics (Canada)
Resverlogix (Canada)
Wilex (Germany)
Biotie Therapeutics (Finland)
Sygnis (Germany)
Achillion Pharmaceuticals (USA)
RXI Pharmaceuticals (USA)
Medigene (Germany)

Source of foundation Managing Director

Categorization
Main sector Investor
Subsector Institutional investor
Public fund

Summary Products / Services / Technologies
Yorkville invests in companies using:

Equity
Convertible Debt
Convertible Preferred
Equity Lines or ATM like products

Financials
Currencies n/a
Financing details No information entered

Collaborations and Clients
Partnering strategy/collaborations
Capital investment in companies to continue with clinical programs.
Client portfolio
Mr. Gilani, Saad  
Managing Director and Head of Life Science Investments

Delegates

Mr. Gilani, Saad

<table>
<thead>
<tr>
<th>Delegate of company</th>
<th>Yorkville Advisors, United States</th>
</tr>
</thead>
<tbody>
<tr>
<td>Position/Function</td>
<td>Managing Director</td>
</tr>
<tr>
<td>Partnering objectives</td>
<td>Providing financing to publicly listed companies to help fund clinical trials, or to use as growth capital</td>
</tr>
<tr>
<td>Professional background</td>
<td>Managing Director and Head- Life Science Investments at Yorkville Advisors, LLC</td>
</tr>
<tr>
<td>Primary area of expertise</td>
<td>Investments in Therapeutics, Diagnostics, Devices, Healthcare Services</td>
</tr>
</tbody>
</table>

Deals you have been involved in:
- Some of the portfolio companies include:
  - Erytech Pharma (France)
  - Santhera Pharma (Switzerland)
  - 4SC (Germany)
  - Epigenomics (Germany)
  - Genfit SA (France)
  - Evolva Holdings (Switzerland)
  - Physiomics PLC (UK)
  - Saruem PLC (UK)
  - Newrwon Pharmaceuticals (Italy/Switzerland)
  - EntreMed (USA)
  - DMedical (Israel)
  - ItN Nanovation (Germany)
  - Sygnis (Germany)
  - Achillion Pharmaceuticals (USA)
  - RXI Pharmaceuticals (USA)
  - Medigene (Germany)
Medicago (Canada)
Allon Therapeutics (Canada)
Resverlogix (Canada)
Wilex (Germany)
Biotie Therapeutics (Finland)
Sygnis (Germany)
Achillion Pharmaceuticals (USA)
RXI Pharmaceuticals (USA)
Medigene (Germany)